var title_f7_63_8176="Management type 2 diabetes";
var content_f7_63_8176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Management of type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 493px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for the metabolic management of type 2 diabetes; Reinforce lifestyle interventions at every visit and check A1C every&nbsp;three months until A1C is &lt;7 percent and then at least every&nbsp;six months. The interventions should be changed if A1C is &ge;7 percent.",
"    <div class=\"footnotes\">",
"     * Sulfonylureas other than glybenclamide (glyburide) or chlorpropamide.",
"     <br>",
"      &bull; Insufficient clinical use to be confident regarding safety.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203. Copyright &copy;2009 American Diabetes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8176=[""].join("\n");
var outline_f7_63_8176=null;
var title_f7_63_8177="Felbinac: International drug information";
var content_f7_63_8177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Felbinac: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dolinac (IT);",
"     </li>",
"     <li>",
"      Dolo Target (CH);",
"     </li>",
"     <li>",
"      Flexfree (BE, LU);",
"     </li>",
"     <li>",
"      Napageln (JP);",
"     </li>",
"     <li>",
"      Seltouch (JP);",
"     </li>",
"     <li>",
"      Traxam (GB, IE, IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inflammatory and analgesic product given for the relief of symptoms associated with soft tissue injuries, rheumatic pain, and nonserious arthritic conditions",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Topical: Apply 2-4 times/day; therapy should be reviewed after 14 days",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Foam: 3% (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Gel: 3% (75 g, 100 g)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10383 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8177=[""].join("\n");
var outline_f7_63_8177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303436\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978855\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978858\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978854\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821106\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978857\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10383\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10383|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_63_8178="Echo apical long axis view MR";
var content_f7_63_8178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/50961/aplamrci_conv.mp4?title=Echo+apical+long+axis+view+MR+\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram apical long axis view of mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical long axis view from 2-D echocardiogram shows mitral regurgitation with a circular \"jet\" directed toward the posterior wall of the left atrium as well as anteriorly toward the interatrial septum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8178=[""].join("\n");
var outline_f7_63_8178=null;
var title_f7_63_8179="AIP plasma cells Light LP";
var content_f7_63_8179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power (40X) view of a pancreas biopsy in a patient with autoimmune pancreatitis showing a large pancreatic duct surrounded by a dense lymphoplasmacytic infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Russell Dorer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8179=[""].join("\n");
var outline_f7_63_8179=null;
var title_f7_63_8180="Hemorrhagic stroke treatment";
var content_f7_63_8180=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/63/8180/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8180/contributors\" id=\"au1625\">",
"       Louis R Caplan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/63/8180/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8180/contributors\" id=\"se4371\">",
"       Scott E Kasner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/63/8180/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8180/contributors\" id=\"de4290\">",
"       Janet L Wilterdink, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/63/8180?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      STROKE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     In the United States, approximately 750,000 strokes occur each year. During a stroke, one or more areas of the brain can be damaged. Depending upon the area affected, a person may lose the ability to move one side of the body, the ability to speak, or a number of other functions. The damage may be temporary or permanent, and the function may be partially or completely lost. A person's long term outcome depends upon how much brain is damaged, how quickly treatment begins, and a number of other factors.",
"    </p>",
"    <p>",
"     Strokes are a leading cause of long-lasting injury, disability, and death. Early treatment and preventive measures can reduce the brain damage that occurs as a result of a stroke. The treatment of a stroke depends upon the type of stroke (eg, ischemic or hemorrhagic), the time since the first stroke symptoms occurred, and the patient's underlying medical problems. General information about the treatment of hemorrhagic strokes is provided here.",
"    </p>",
"    <p>",
"     A separate topic review is available that discusses the signs, symptoms, and diagnosis of ischemic and hemorrhagic strokes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .) A topic is also available that discusses the treatment of ischemic stroke. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"      \"Patient information: Ischemic stroke treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS A HEMORRHAGIC STROKE?",
"     </span>",
"    </p>",
"    <p>",
"     Hemorrhage is the medical term for bleeding. Hemorrhagic stroke occurs when blood vessels in the brain leak or rupture, causing bleeding in or around the brain. About 20 percent of strokes are hemorrhagic strokes. Damage can occur quickly due to the pressure of increasing amounts of blood or because of the blood itself. Blood is irritating to the brain tissue, causing it to swell.",
"    </p>",
"    <p>",
"     Bleeding around the brain is referred to as subarachnoid hemorrhage (SAH) and is often caused by rupture of an abnormal blood vessel (aneurysm) on the surface of the brain. Bleeding into the brain is called intracerebral hemorrhage (ICH) and is often caused by high blood pressure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      STROKE TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17152723\">",
"     <span class=\"h2\">",
"      Medical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The treatment of a hemorrhagic stroke depends upon the cause of the bleeding (eg, high blood pressure, use of anticoagulant medications, head trauma, blood vessel malformation). Most patients are monitored closely in an intensive care unit during and after a hemorrhagic stroke. The initial care of a person with hemorrhagic stroke includes several components:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Determining the cause of the bleeding.",
"      </li>",
"      <li>",
"       Controlling the blood pressure.",
"      </li>",
"      <li>",
"       Stopping any medication that could increase bleeding (eg, warfarin, aspirin). If the patient has been taking warfarin, specific treatments such as factor VIIa or transfusions of blood clotting factors, may be given to stop ongoing bleeding.",
"      </li>",
"      <li>",
"       Measuring and controlling the pressure within the brain.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Pressure within the brain can be measured by placing a device, known as a ventriculostomy tube, through the skull into an area of the brain called the ventricle. If the pressure is elevated, a small amount of cerebrospinal fluid can be removed from the ventricle. A ventriculostomy can also be used to drain blood that has collected in the brain as a result of the stroke. The procedure can be done at the patient's bedside or in an operating room.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Surgical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;A surgical procedure may be recommended to prevent or stop bleeding or reduce the pressure inside the skull. Depending upon the stroke severity and the patient's condition, surgery may be done within the first 48 to 72 hours after the hemorrhage, or it may be delayed until one to two weeks later to allow the patient's condition to stabilize.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Aneurysm treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;An aneurysm is a blood vessel that has a weak area that balloons out. If the area ruptures and bleeds, a hemorrhagic stroke can occur.",
"    </p>",
"    <p>",
"     A clamp can be placed at the base of the aneurysm to prevent bleeding before a stroke or to prevent re-bleeding. This surgery requires removing a piece of the skull and locating the aneurysm within the brain tissue. This procedure is done after the patient is given general anesthesia, and often requires several hours to complete. The piece of skull is replaced at the end of the surgery.",
"    </p>",
"    <p>",
"     Coil embolization is an interventional procedure that is less invasive than clipping and can be done while the patient is sedated or put to sleep with medications. It involves inserting a flexible tube (catheter) into an artery in the groin. The catheter is guided along blood vessels in the body into the vessel in the brain where the aneurysm is located. A tiny coil is advanced into the weakened area (aneurysm), filling the area with the coil. A blood clot forms within the coil, blocking blood flow into the aneurysm and preventing it from rupturing again. Other materials may also be injected to obliterate an aneurysm or AVM.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Arteriovenous malformation treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some arteriovenous malformations (AVMs) have a significant risk of further bleeding. The decision to treat an AVM depends on several factors; the main factors are the patient age, AVM location and size, and abnormalities of the veins that drain the malformation and whether or not the AVM has previously bled. Treatment could include surgery, radiosurgery (use of radiation to shrink blood vessels), or embolization techniques.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17152730\">",
"     <span class=\"h3\">",
"      Decompressive craniotomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;When a patient&rsquo;s life appears to be threatened because of the pressure effects of a blood clot in the brain, the physician may consider a procedure to open the skull",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     remove the blood. Considerations include the location and size of the hemorrhage, the patient&rsquo;s age and medical condition, and the likelihood of making a recovery from the stroke.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      STROKE COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     A number of problems can develop in people who have had a stroke. These complications are significant because approximately half of deaths after stroke are due to medical complications. In the days and weeks after a stroke, clinicians, the patient, and family members can work to decrease the risk of some of these complications. Common complications include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Blood clots",
"      </li>",
"      <li>",
"       Difficulty eating and drinking, which increases the risk of pneumonia and malnutrition",
"      </li>",
"      <li>",
"       Urinary tract infection",
"      </li>",
"      <li>",
"       Bleeding in the digestive system",
"      </li>",
"      <li>",
"       Heart attack or heart failure",
"      </li>",
"      <li>",
"       Bed sores",
"      </li>",
"      <li>",
"       Falls",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Blood clots",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have strokes are at increased risk of developing blood clots as they recover. A deep vein thrombosis (DVT) is a blood clot that develops in the deep veins of the leg. If the clot breaks off, it can travel to the lung, where it is called a pulmonary embolus (PE). A PE can cause serious and potentially fatal, changes in blood flow throughout the body. These blood clots occur most often between the second and seventh day after the stroke.",
"    </p>",
"    <p>",
"     The risk of pulmonary embolism is especially high in stroke patients who have difficulty with moving or walking around during the recovery period. Difficulty walking may be related to paralysis caused by the stroke or to other medical conditions. Lack of movement increases the risk of a deep vein thrombosis. To decrease the risk of blood clots, the patient is encouraged to get up and move around frequently as soon as they are able to do so. A physical therapist is often available to help, especially if the patient has weakness in the legs as a result of the stroke.",
"    </p>",
"    <p>",
"     Heparin or low molecular weight heparin are used commonly to prevent a blood clot in a deep vein of the leg or a blood clot that travels to the lung. The benefits of heparin in preventing a pulmonary embolus must be balanced with the increased risk of bleeding related to heparin. An effective alternative for preventing blood clots in the legs are special stockings that are put around the patient&rsquo;s calves that provide intermittent pneumatic compression. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Difficulty swallowing",
"     </span>",
"     &nbsp;&mdash;&nbsp;The act of swallowing requires coordination of the nerves and muscles of the tongue, mouth, and throat. The brain damage that occurs as a result of a stroke can cause muscle weakness and difficulty swallowing. Dysphagia is the medical term for difficulty swallowing.",
"    </p>",
"    <p>",
"     Dysphagia is concerning because it increases the risk of inhaling saliva or food into the lungs, which can cause a type of pneumonia known as aspiration pneumonia. Patients with stroke-related pneumonia have a higher risk of death and a poorer long-term outcome when compared to patients without pneumonia. However, in people who have weakness of one side of the body, dysphagia is often temporary because both sides of the brain and body control swallowing.",
"    </p>",
"    <p>",
"     To determine if a patient is at risk for inhaling food or drinks into the lungs, a simple water swallow test may be done. If the patient has difficulty swallowing water, the clinician may recommend that the patient not eat or drink anything temporarily. In the meantime, medication and nutrition can be given into a vein. Specific exercises and training programs can help to retrain a person how to swallow despite muscle or nerve damage. An additive to thicken liquids may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Urinary tract infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a stroke, some men and women have difficulty getting out of bed to empty their bladder. Others have difficulty with urinary leakage or are not able to empty their bladder completely because of muscle weakness. For these reasons, a catheter is often placed inside the bladder, especially during the first few days to weeks after a stroke. However, there is an increased risk of urinary tract infections related to the use of a catheter.",
"    </p>",
"    <p>",
"     Urinary tract infections are a common complication after stroke, occurring in about 11 percent of patients during the first three months after stroke [",
"     <a class=\"abstract\" href=\"UTD.htm?7/63/8180/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     There are a number of strategies that can decrease the risk of urinary tract infections in patients who require a catheter. A few of these strategies are listed below:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use a catheter only when necessary",
"      </li>",
"      <li>",
"       Remove the catheter as soon as possible",
"      </li>",
"      <li>",
"       It is not necessary to change the catheter to prevent infections. The catheter should only be changed if it begins to crack or deteriorate or if the patient has a urinary tract infection.",
"      </li>",
"      <li>",
"       For men, there is a lower risk of infections with a condom-type catheter.",
"      </li>",
"      <li>",
"       There are not good data to support using antibiotics to",
"       <strong>",
"        prevent",
"       </strong>",
"       infection during catheter use. Antibiotics are recommended to treat a urinary tract infection if it develops.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17152715\">",
"     <span class=\"h2\">",
"      Seizures",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of seizures in patients who have had a hemorrhagic stroke ranges from 5 to 30 percent, depending in part on the cause and the location of the seizure.",
"    </p>",
"    <p>",
"     Patients who have a seizure are treated with antiepileptic drugs to prevent the seizures from recurring. Some physicians may choose to start seizure medication as a preventive measure even if a seizure has not occurred.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Nutrition",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a stroke, some patients have difficulty consuming an adequate number of calories. In addition, some patients are underweight or malnourished before their stroke. These problems can interfere with a person's ability to recover from stroke, potentially increasing the risk of long-term disability.",
"    </p>",
"    <p>",
"     For these reasons, a patient's nutritional status should be evaluated before discharge from the hospital. This includes a review of the patient's past and current body weight, a basic history of the patient's eating habits, blood testing, and a physical examination that focuses on the condition of the eyes, hair, skin, mouth, and muscles.",
"    </p>",
"    <p>",
"     If a person is not able to consume an adequate number of calories, a feeding tube may be placed through the nose and into the stomach (called a nasogastric tube). If the feeding tube will be needed for more than two to three weeks, a tube can be inserted through the abdomen into the stomach (called a percutaneous endoscopic gastrostomy (PEG) tube). The PEG tube may be removed if the person regains the ability to eat normally.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      GI bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who have had a severe stroke, especially those who are in the intensive care unit and require a ventilator to breathe, have an increased risk of developing a bleeding ulcer in the stomach. To lower this risk, a medication can be given to lower the stomach's production of acid.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Heart problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heart problems, such as an irregular heart rhythm (called an arrhythmia) or heart attack (called a myocardial infarction) are commonly seen following stroke, with some heart problems occurring in up to 70 percent of people. It is important to determine whether the heart problems are caused by the stroke, unrelated to it, or the cause of the stroke. &nbsp;Tests commonly performed to screen for these problems include an electrocardiogram (ECG), blood testing, and continuous monitoring of the heart rhythm (called telemetry). In some cases, the person may not be able to tell the clinician that he or she feels chest pain. The ECG will help the clinician to diagnose and treat heart problems as quickly as possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Bed sores",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bed sores are areas of skin and underlying tissue that are injured when compressed between a bone (eg, tail bone) and an external surface (eg, a mattress) for a prolonged period of time. Other names for bed sores are pressure sores and decubitus ulcers.",
"    </p>",
"    <p>",
"     The consequences of this type of skin injury range from mild skin redness to deep ulcers extending down to the bone. The ulcer can be uncomfortable and increases the risk of infection for the patient and also potentially increases the healthcare costs and hospital stay.",
"    </p>",
"    <p>",
"     Bed sores are common in people with a limited ability to move without assistance, and may be preventable by moving or turning (or being moved by a family member or nurse) at least every two hours. It is recommended that:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Patients should be placed at a 30 degree angle when lying on their side to avoid direct pressure over the hip bone (greater trochanter).",
"      </li>",
"      <li>",
"       Pillows or foam wedges may need to be placed between the ankles and knees to avoid pressure at these sites.",
"      </li>",
"      <li>",
"       The heels require particular attention; pillows may be placed under the lower legs to elevate the heels, or special heel protectors can be used.",
"      </li>",
"      <li>",
"       Elevation of the head of the bed should be limited.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Chair-bound patients may generate considerable pressures over the sit bones (ischial tuberosities); they should probably be repositioned at least every hour.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Falls",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a stroke, many people have difficulty walking due to muscle weakness, paralysis, or lack of coordination. When a person becomes less active or unable to walk, they are at increased risk of bone thinning (osteoporosis), blood clots, and worsened muscle weakness. These risks greatly increase the chance of breaking a bone after a fall. Falls are one of the most common complications of stroke, occurring in up to 25 percent of patients.",
"    </p>",
"    <p>",
"     To reduce the risk of falls, several interventions may be helpful:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Muscle strengthening and balance retraining exercises &mdash; This may include exercise or rehabilitation programs tailored to an individual's needs and abilities. Group classes, such as Tai Chi, may be helpful for patients who are able to walk without assistance.",
"      </li>",
"      <li>",
"       Evaluation of fall risk &mdash; An evaluation may be recommended to determine if a person is at risk for falling. If there is a risk of falling, treatments (eg, a walker, balance training) may be recommended to decrease the risk.",
"      </li>",
"      <li>",
"       Home hazards &mdash; Home hazards such as poor lighting or loose rugs can increase the risk of falling. The following tips can reduce this risk:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Remove loose rugs, electrical cords, or other items that could lead to tripping, slipping, and falling",
"      </li>",
"      <li>",
"       Ensure that there is adequate lighting in all areas inside and around the home (including stairwells and entrance ways)",
"      </li>",
"      <li>",
"       Avoid walking on ice, wet or polished floors, or other potentially slippery surfaces, and avoid walking in unfamiliar areas outside",
"      </li>",
"      <li>",
"       Ensure that the person has properly fitted, non-slip footwear",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      STROKE OUTCOME",
"     </span>",
"    </p>",
"    <p>",
"     A patient's healthcare team can often provide guidance to family members regarding the patient's risk of long-term disability or death. However, it may difficult to know exactly what to expect, and in most cases, it is necessary to watch and wait.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1196458\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1196465\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/17/5394?source=see_link\">",
"      Patient information: Brain aneurysm (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=see_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/19/30002?source=see_link\">",
"      Patient information: Subarachnoid hemorrhage (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=see_link\">",
"      Patient information: Transient ischemic attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/42/26274?source=see_link\">",
"      Patient information: Arteriovenous malformations in the brain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/61/30674?source=see_link\">",
"      Patient information: Aphasia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3795?source=see_link\">",
"      Patient information: Recovery after stroke (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1196473\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1196481\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33348?source=see_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"      Brain arteriovenous malformations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/stroke/stroke.htm\">",
"      www.ninds.nih.gov/disorders/stroke/stroke.htm",
"     </a>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Stroke Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.strokeassociation.org/\">",
"      www.strokeassociation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Stroke Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.stroke.org/\">",
"      www.stroke.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Several books are also recommended:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Caplan, LR. Stroke, American Academy of Neurology and Demos Publishers, New York 2006.",
"      </li>",
"      <li>",
"       Hutton C, Caplan, LR. Striking back at stroke: a doctor-patient journal, Dana Press, New York 2003.",
"      </li>",
"      <li>",
"       Hutton C. After a stroke: 300 tips for making life easier, Demos, New York 2005.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?7/63/8180/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/63/8180?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8180/abstract/1\">",
"      Johnston KC, Li JY, Lyden PD, et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 1998; 29:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8180/abstract/2\">",
"      Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003; 34:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8180/abstract/3\">",
"      Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8180/abstract/4\">",
"      Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2003; :CD000029.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_63_8180=[""].join("\n");
var outline_f7_63_8180=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           STROKE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS A HEMORRHAGIC STROKE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           STROKE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           STROKE COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           STROKE OUTCOME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_63_8181="Pseudoephedrine and ibuprofen: Patient drug information";
var content_f7_63_8181=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pseudoephedrine and ibuprofen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36791?source=see_link\">",
"     see \"Pseudoephedrine and ibuprofen: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/46/31462?source=see_link\">",
"     see \"Pseudoephedrine and ibuprofen: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg; Cold &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Proprinal&reg; Cold and Sinus [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg; Cold &amp; Sinus;",
"     </li>",
"     <li>",
"      Advil&reg; Cold &amp; Sinus Daytime;",
"     </li>",
"     <li>",
"      Children's Advil&reg; Cold;",
"     </li>",
"     <li>",
"      Sudafed&reg; Sinus Advance",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702823",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pseudoephedrine, ibuprofen, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703758",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had recent heart bypass surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any type of nuts or seeds, talk with your doctor. Some products have nuts in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697079",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking aspirin to stop a heart attack, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11008 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8181=[""].join("\n");
var outline_f7_63_8181=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215437\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215438\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017938\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017940\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017939\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017944\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017945\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017947\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017942\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017943\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017948\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017949\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36791?source=related_link\">",
"      Pseudoephedrine and ibuprofen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/46/31462?source=related_link\">",
"      Pseudoephedrine and ibuprofen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_63_8182="Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients";
var content_f7_63_8182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8182/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8182/contributors\">",
"     David H Spach, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8182/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8182/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8182/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8182/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/63/8182/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartonella infections can cause serious morbidity and mortality in HIV-infected patients, particularly those with advanced immunosuppression.",
"   </p>",
"   <p>",
"    This topic will address the epidemiology, microbiology and clinical manifestations of Bartonella infections in HIV-infected patients. The diagnosis, treatment, and prevention of these infections are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18469?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of Bartonella infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other aspects of Bartonella infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26503?source=see_link\">",
"     \"Bartonellosis: Oroya fever and verruga peruana\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14119129\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more than 15 distinct species of Bartonella have been isolated, only two Bartonella species cause clinically relevant infections in individuals infected with the human immunodeficiency virus (HIV): Bartonella henselae and B. quintana [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14119136\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with B. henselae infection usually have an epidemiologic link to cat exposure, whereas B. quintana infections have predominantly involved homeless persons with head or body lice exposure. Bartonella infection develops more commonly in patients with HIV infection and advanced immune suppression (eg, &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3).",
"    </span>",
"    In one study, 42 HIV-infected patients with B. henselae had a median CD4 count of 21",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients often present with cutaneous violaceous lesions, which can also involve other internal organs; this form of disease is called bacillary angiomatosis. Peliosis hepatis pertains to Bartonella infection of the liver.",
"   </p>",
"   <p>",
"    Although reports of bacillary angiomatosis and peliosis hepatis have most often involved HIV-infected individuals, other immunocompromised individuals, such as cancer patients and solid organ transplant recipients, have also developed these manifestations. One study of epidemiologic and clinical data on HIV-associated bacillary angiomatosis in Germany found a prevalence of 1.2 cases per 1000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/4\">",
"     4",
"    </a>",
"    ]. A serologic study in Spain comparing HIV-infected persons with HIV-negative blood donors found a higher percentage with B. henselae immunofluorescent antibody (IFA) titers &ge;1:64 (9 of 52 [17 percent] versus 5 of 85 [5 percent], respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/5\">",
"     5",
"    </a>",
"    ]. In a more contemporary study involving HIV-infected individuals in Greece, 41 percent had positive IgG antibodies to B. henselae, but the investigators did not show any correlation of these results with clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the true incidence of Bartonella infections in HIV-infected patients is likely much lower with the era of potent antiretroviral therapy (ART).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14119143\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartonella species can produce a broad array of manifestations, including bacillary angiomatosis, bacillary peliosis, splenitis, osteomyelitis, and bacteremia. In one study of 49 patients with Bartonella-associated infections, 46 of whom were HIV-infected, the two species had differing organ tropism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/7\">",
"     7",
"    </a>",
"    ]. B. henselae was the major cause of lymph node, liver, and splenic lesions, whereas B. quintana was the predominant cause of bone or subcutaneous masses; either organism appeared equally capable of causing cutaneous lesions.",
"   </p>",
"   <p>",
"    With all forms of bacillary angiomatosis, patients may have constitutional symptoms, including fever, chills, malaise, headache, and anorexia with or without weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Bacillary angiomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacillary angiomatosis is characterized by unique vascular lesions that most frequently involve the skin, but can affect other organs, such as the respiratory tract, bone, lymph nodes, gastrointestinal tract, and brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Cutaneous lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous lesions in BA may appear as angiomatous lesions that are difficult to diagnose because of the differing appearances. The lesions most frequently consist of papular, nodular, pedunculated, or verrucous forms. They typically first develop as small red to purple papules that may gradually expand into large pedunculated lesions or nodules that may become friable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The surface generally starts off smooth but subsequently may erode, with or without crusting. The lesions usually have a vascular appearance and may bleed profusely with trauma (",
"    <a class=\"graphic graphic_picture graphicRef78497 graphicRef82760 graphicRef82759 \" href=\"UTD.htm?40/17/41242\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most often, BA lesions are solitary or several in number, but rarely may appear in a disseminated version manifested by more than 1000 small lesions. Infrequently observed forms of cutaneous bacillary angiomatosis include a cellulitic plaque that often overlies an osteolytic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/8\">",
"     8",
"    </a>",
"    ] and hyperpigmented, hyperkeratotic plaques that have scaling and minimal superficial evidence of vascularity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous BA lesions may resemble Kaposi's sarcoma, pyogenic granuloma, cherry angioma, dermatofibroma, hemangioma, and verruga peruana, the cutaneous lesions associated with South American bartonellosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26503?source=see_link\">",
"     \"Bartonellosis: Oroya fever and verruga peruana\"",
"    </a>",
"    .) The nodular and plaque forms of BA may resemble lesions caused by mycobacteria, tuberculosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Subcutaneous lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous lesions may develop as deeper seated, tender nodules that have erythematous or normal-appearing overlying skin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/8\">",
"     8",
"    </a>",
"    ]. These lesions can erode through the cutaneous surface and become superinfected. Less frequently, the lesions develop as an enlarging deep suppurative ulcer (",
"    <a class=\"graphic graphic_picture graphicRef82761 \" href=\"UTD.htm?33/57/34710\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Osseous lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone involvement in patients with BA is not uncommon; in one series, 6 of 17 patients with cutaneous BA had symptomatic osteolytic bone lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/12\">",
"     12",
"    </a>",
"    ]. Rarely, focal osteomyelitis has developed prior to any other manifestation of BA. Patients with bone involvement present with painful bone lesions, most often involving long bones such as the tibia, fibula, and radius. These patients also often have an overlying cellulitic plaque. Bone radiographs show lytic lesions; technetium scans show increased uptake at these same sites. Bone lesions can range from focal well-circumscribed lytic areas to ill-defined areas that show aggressive cortical destruction with notable periosteal reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mucosal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous lesions of BA are often widespread and can affect the mucosa. Conversely, oral lesions can occur without cutaneous manifestations. Several reports have described lesions on the gingival region, buccal mucosa, oral labial mucosa, hard palate, and posterior pharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/13\">",
"     13",
"    </a>",
"    ]. The mucosal lesions appear as smooth purple papules or plaques that may resemble pyogenic granuloma or Kaposi's sarcoma. Rarely, patients may develop a conjunctival, nodular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report described a patient with intracerebral BA; this patient had a 2 cm mass lesion that preceded the development of a cutaneous BA lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/15\">",
"     15",
"    </a>",
"    ]. Brain biopsy studies, including Warthin-Starry staining and electron microscopy, showed evidence of typical-appearing Bartonella bacilli. The patient had a gradual, but dramatic clinical and radiographic response to a prolonged course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . An additional probable, but not confirmed, case of BA involved a patient with trigeminal neuralgia, low back pain, and spine magnetic resonance imaging findings suggesting vascular defects in L3 and L4 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/16\">",
"     16",
"    </a>",
"    ]. This patient's lesions resolved with antibiotic therapy. Other reports have described aseptic meningitis, dementia, and psychiatric symptoms possibly related to Bartonella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, a large study using the San Diego HIV Neurobehavioral Research Study database failed to show any correlation between B. henselae serostatus and neurocognitive decline [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bacillary peliosis and splenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first report of bacillary peliosis among HIV-infected persons appeared in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/20\">",
"     20",
"    </a>",
"    ]. In this report, liver biopsy specimens from eight patients showed cystic blood filled spaces in the hepatic parenchyma and clumps of granular purple material; both Warthin-Starry staining and electron microscopy identified this granular purple material as bacilli identical to those found in patients with cutaneous BA. Patients had hepatomegaly and increases in alkaline phosphatase of approximately five times normal. Six of the eight patients also had splenomegaly; two of three patients whose splenic tissue was analyzed had evidence of splenic peliosis. Two of these eight patients had concomitant cutaneous BA.",
"   </p>",
"   <p>",
"    One case report has described a 29-year-old with fever, abdominal pain, vomiting, anorexia, and hepatomegaly who was discovered to have massive hemoperitoneum and hypovolemic shock as the main manifestation of hepatic bacillary parenchymal peliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/21\">",
"     21",
"    </a>",
"    ]. This case highlights the importance of including bacillary peliosis and bacillary angiomatosis in the differential diagnosis of fever and abdominal pain in HIV-infected patients. Although rare, the risk of hepatic hemorrhage in bacillary peliosis should be considered in the setting of a HIV-infected patient with hypovolemic shock.",
"   </p>",
"   <p>",
"    Subsequent reports have noted thrombocytopenia or pancytopenia in patients with peliosis hepatis and splenitis. Patients with splenitis can have an acute necrotizing inflammatory response without evidence of angiomatosis. Abdominal computed tomography typically shows organomegaly and hypodense lesions scattered throughout the organ parenchyma. However, other conditions can produce similar radiographic findings, such as lymphoma, disseminated Mycobacterium avium complex, and extrapulmonary Pneumocystis pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bacteremia, endocarditis, and unexplained fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected persons with BA or peliosis hepatis may also occasionally have blood cultures positive for Bartonella. In one report, extended incubation blood cultures identified two cases of Bartonella infection among 45 AIDS patients who had unexplained fever [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/22\">",
"     22",
"    </a>",
"    ]. A few reports have described Bartonella-associated endocarditis among HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because isolation of the Bartonella organisms in culture remains difficult, bacteremia is probably significantly underdiagnosed. In a study of 382 patients with unexplained fever (95 percent infected with HIV), 68 (18 percent) had evidence of Bartonella infection by culture, polymerase chain reaction, or indirect immunofluorescence antibody testing; only 11 patients had Bartonella isolated from blood or tissue specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8182/abstract/24\">",
"     24",
"    </a>",
"    ]. Most of the patients with evidence of Bartonella infection had advanced HIV disease and a CD4 count less than 100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    It is not clear that all cases of unexplained fever in patients in the study with evidence of Bartonella infection were actually due to Bartonella; no information on therapy and follow-up was provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14119273\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bartonella infections can cause serious morbidity and mortality in HIV-infected patients, particularly those with advanced immunosuppression. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two Bartonella species cause clinically relevant infections in individuals infected with HIV: Bartonella henselae and Bartonella quintana. (See",
"      <a class=\"local\" href=\"#H14119129\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with B. henselae infection usually have an epidemiologic link to cat exposure, whereas B. quintana infections have predominantly involved homeless persons with head or body lice exposure. (See",
"      <a class=\"local\" href=\"#H14119136\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bartonella species can produce a broad array of manifestations, including bacillary angiomatosis, bacillary peliosis, splenitis, osteomyelitis, and bacteremia. Common constitutional symptoms include fever, chills, malaise, headache, and anorexia with or without weight loss. (See",
"      <a class=\"local\" href=\"#H14119143\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacillary angiomatosis is characterized by unique vascular lesions that most frequently involve the skin, but can affect other organs, such as the respiratory tract, bone, lymph nodes, gastrointestinal tract, and brain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bacillary angiomatosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous lesions in bacillary angiomatosis may appear as angiomatous lesions that are difficult to diagnose because of the differing appearances. The lesions most frequently consist of papular, nodular, pedunculated, or verrucous forms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cutaneous lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with bacillary peliosis and splenitis present with fever, weight loss, hepatomegaly, and often splenomegaly. Concomitant cutaneous Bartonella lesions may be seen occasionally. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bacillary peliosis and splenitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected persons with bacillary angiomatosis or peliosis hepatis may also occasionally have bacteremia as well. Bacteremia may be underdiagnosed in patients with disseminated disease due to the fastidious nature of the organism. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bacteremia, endocarditis, and unexplained fever'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/1\">",
"      Koehler JE, Quinn FD, Berger TG, et al. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992; 327:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/2\">",
"      Cotell SL, Noskin GA. Bacillary angiomatosis. Clinical and histologic features, diagnosis, and treatment. Arch Intern Med 1994; 154:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/3\">",
"      Mohle-Boetani JC, Koehler JE, Berger TG, et al. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Clin Infect Dis 1996; 22:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/4\">",
"      Plettenberg A, Lorenzen T, Burtsche BT, et al. Bacillary angiomatosis in HIV-infected patients--an epidemiological and clinical study. Dermatology 2000; 201:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/5\">",
"      Blanco JR, Oteo JA, Mart&iacute;nez V, et al. [Seroepidemiology of Bartonella henselae infection in HIV-infected patients]. Enferm Infecc Microbiol Clin 1999; 17:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/6\">",
"      Pape M, Kollaras P, Mandraveli K, et al. Occurrence of Bartonella henselae and Bartonella quintana among human immunodeficiency virus-infected patients. Ann N Y Acad Sci 2005; 1063:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/7\">",
"      Koehler JE, Sanchez MA, Garrido CS, et al. Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med 1997; 337:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/8\">",
"      Koehler JE, Tappero JW. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/9\">",
"      Tappero JW, Perkins BA, Wenger JD, Berger TG. Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin Microbiol Rev 1995; 8:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/10\">",
"      Webster GF, Cockerell CJ, Friedman-Kien AE. The clinical spectrum of bacillary angiomatosis. Br J Dermatol 1992; 126:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/11\">",
"      Carrascosa JM, Ribera M, Bielsa I, et al. Bacillary angiomatosis presenting as a malleolar ulcer. Arch Dermatol 1995; 131:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/12\">",
"      Baron AL, Steinbach LS, LeBoit PE, et al. Osteolytic lesions and bacillary angiomatosis in HIV infection: radiologic differentiation from AIDS-related Kaposi sarcoma. Radiology 1990; 177:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/13\">",
"      Monteil RA, Michiels JF, Hofman P, et al. Histological and ultrastructural study of one case of oral bacillary angiomatosis in HIV disease and review of the literature. Eur J Cancer B Oral Oncol 1994; 30B:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/14\">",
"      Lee WR, Chawla JC, Reid R. Bacillary angiomatosis of the conjunctiva. Am J Ophthalmol 1994; 118:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/15\">",
"      Spach DH, Panther LA, Thorning DR, et al. Intracerebral bacillary angiomatosis in a patient infected with human immunodeficiency virus. Ann Intern Med 1992; 116:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/16\">",
"      Harris PJ. Intracerebral bacillary angiomatosis in HIV. Ann Intern Med 1992; 117:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/17\">",
"      Marra CM. Neurologic complications of Bartonella henselae infection. Curr Opin Neurol 1995; 8:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/18\">",
"      Baker J, Ruiz-Rodriguez R, Whitfeld M, et al. Bacillary angiomatosis: a treatable cause of acute psychiatric symptoms in human immunodeficiency virus infection. J Clin Psychiatry 1995; 56:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/19\">",
"      Wallace MR, Persing DH, McCutchan JA, et al. Bartonella henselae serostatus is not correlated with neurocognitive decline in HIV infection. Scand J Infect Dis 2001; 33:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/20\">",
"      Perkocha LA, Geaghan SM, Yen TS, et al. Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection. N Engl J Med 1990; 323:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/21\">",
"      Lozano F, Corzo JE, Le&oacute;n EM, et al. Massive hemoperitoneum: a new manifestation of bacillary peliosis in human immunodeficiency virus infection. Clin Infect Dis 1999; 28:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/22\">",
"      Dougherty MJ, Spach DH, Larson AM, et al. Evaluation of an extended blood culture protocol to isolate fastidious organisms from patients with AIDS. J Clin Microbiol 1996; 34:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/23\">",
"      Spach DH, Callis KP, Paauw DS, et al. Endocarditis caused by Rochalimaea quintana in a patient infected with human immunodeficiency virus. J Clin Microbiol 1993; 31:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8182/abstract/24\">",
"      Koehler JE, Sanchez MA, Tye S, et al. Prevalence of Bartonella infection among human immunodeficiency virus-infected patients with fever. Clin Infect Dis 2003; 37:559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5512 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8182=[""].join("\n");
var outline_f7_63_8182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14119273\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14119129\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14119136\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14119143\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Bacillary angiomatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Subcutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Osseous lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mucosal lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bacillary peliosis and splenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bacteremia, endocarditis, and unexplained fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14119273\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5512\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5512|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/47/27383\" title=\"picture 1A\">",
"      Bacillary angiomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/31/26103\" title=\"picture 1B\">",
"      Cutaneous bacillary angiomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/9/30869\" title=\"picture 1C\">",
"      Cutaneous bacillary angiomatosis above eyebrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/57/34710\" title=\"picture 2\">",
"      Ulcerative lesion secondary to bacillary angiomatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26503?source=related_link\">",
"      Bartonellosis: Oroya fever and verruga peruana",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18469?source=related_link\">",
"      Diagnosis, treatment, and prevention of Bartonella infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31830?source=related_link\">",
"      Endocarditis caused by Bartonella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_63_8183="Brimonidine and timolol: Drug information";
var content_f7_63_8183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brimonidine and timolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/46/35556?source=see_link\">",
"    see \"Brimonidine and timolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5578883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Combigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5067249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Combigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5067382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha;",
"      <sub>",
"       2",
"      </sub>",
"      Agonist, Ophthalmic",
"     </li>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5074645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glaucoma, ocular hypertension: Ophthalmic: Instill 1 drop into affected eye(s) twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5578906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glaucoma, ocular hypertension: Children &ge;2 years: Ophthalmic: Instill 1 drop into affected eye(s) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In the Canadian labeling, use in children (at any age) is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5074646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5074649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combigan&reg;: Brimonidine tartrate 0.2% and timolol 0.5% (5 mL,10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combigan&reg;: Brimonidine tartrate 0.2% and timolol maleate 0.5% (2.5 mL, 5 mL,10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5067380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5074647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer approximately every 12 hours. Remove contact lenses prior to administration; wait 15 minutes before reinserting if using products containing benzalkonium chloride. Separate administration of other ophthalmic agents by 5-10 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5067383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5067246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Combigan&reg; may be confused with Combivent&reg;, Comtan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5073798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported with combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5% to 15%: Ocular: Allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, pruritus, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Somnolence (children 25% to 83%), depression, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blepharitis, blurred vision, corneal erosion, dry eyes, epiphora, eye discharge, eye pain, eyelid edema, eyelid erythema, eye irritation, eyelid pruritus, foreign body sensation, superficial punctuate keratitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5067388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brimonidine, timolol, or any other component of the formulation; current or history of bronchial asthma, severe chronic obstructive pulmonary disease (COPD); sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, cardiogenic shock; children &lt;2 years of age.  Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Monoamine oxidase (MAO) inhibitor therapy (concurrent or within 14 days)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5073794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to a variety of allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has the potential to cause bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Ocular hypersensitivity reactions have been reported with brimonidine; reactions may cause an increase in intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular effects: Use of agents that reduce/suppress aqueous humor production has been associated with choroidal detachment after filtration procedures. Discontinue use in patients with chronic or recurrent choroidal detachment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Orthostatic hypotension: Use with caution. Signs and symptoms of hypotension may be enhanced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angle-closure glaucoma: Appropriate use: Not for use alone to treat acute angle-closure glaucoma (has no effect on papillary constriction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease (eg, asthma, COPD) should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Conduction abnormalities: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen myasthenia-related muscle weakness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal Impairment: Use with caution in patients with renal impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Beta-blockers: Concomitant use with other topical beta-blockers should be avoided; monitor for increased effects (systemic or intraocular) with concomitant use of a systemic beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Contact lens wearers: Product contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;2 years of age; use contraindicated in children &lt;2 years of age.",
"     <b>",
"      Note:",
"     </b>",
"     In the Canadian labeling, use in children (at any age) is not recommended. Serious adverse reactions (eg, bradycardia, hypotension, apnea, dyspnea, cyanosis) resulting in hospitalization have been reported in association with brimonidine administration in infants ages 28 days to 3 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Absorption: Systemic absorption of timolol and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension. Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia. Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5073829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5073824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5578884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5067384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women with the combination product. Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5067386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (timolol)/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5067387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timolol has been detected in human breast milk following ophthalmic administration. It is not known if brimonidine is excreted in human milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5574883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Combigan Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2-0.5% (5 mL): $112.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5578907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure; monitor for systemic effect of beta-blockade with ophthalmic administration; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5067251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Combigan (AR, AT, AU, BE, BR, CH, CN, CO, CZ, DE, DK, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, MY, NL, NO, NZ, PE, PH, PL, PT, SE, SG, TH, TW, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5074642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brimonidine: Selective agonism for alpha",
"     <sub>",
"      2",
"     </sub>",
"     -receptors; causes reduction of aqueous humor formation and increased uveoscleral outflow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timolol: Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, reduces intraocular pressure by reducing aqueous humor production or possibly outflow; reduces blood pressure by blocking adrenergic receptors and decreasing sympathetic outflow, produces a negative chronotropic and inotropic activity by blocking beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5073834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Frampton JR, &ldquo;Topical Brimonidine 0.2%/Timolol 0.5% Ophthalmic Solution In Glaucoma and Ocular Hypertension,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 2006, 23(9):753-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8183/abstract-text/17020399/pubmed\" id=\"17020399\" target=\"_blank\">",
"        17020399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8183/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larsson LI, &ldquo;Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Timolol, Alone and in Combination,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2001, 119(4):492-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8183/abstract-text/11296014/pubmed\" id=\"11296014\" target=\"_blank\">",
"        11296014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sherwood MB, Craven ER, Chou C, et al, &ldquo;Twice-Daily 0.2% Brimonidine-0.5% Timolol Fixed-Combination Therapy vs Monotherapy With Timolol or Brimonidine in Patients With Glaucoma or Ocular Hypertension: A 12-Month Randomized Trial,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2006, 124(9):1230-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8183/abstract-text/16966616/pubmed\" id=\"16966616\" target=\"_blank\">",
"        16966616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stewart WC, Stewart JA, and Jackson AL, &ldquo;Cardiovascular Effects of Timolol Maleate, Brimonidine, or Brimonidine/Timolol Maleate in Concomitant Therapy,&rdquo;",
"      <i>",
"       Acta Ophthalmol Scand",
"      </i>",
"      , 2002, 80(3):277-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8183/abstract-text/12059866/pubmed\" id=\"12059866\" target=\"_blank\">",
"        12059866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8773 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8183=[""].join("\n");
var outline_f7_63_8183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5578883\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067249\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067382\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5074645\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5578906\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5074646\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5074649\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950026\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067380\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5074647\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067383\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067246\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5073798\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067388\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5073794\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5073829\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5073824\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5578884\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067384\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067386\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067387\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5574883\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5578907\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067251\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5074642\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5073834\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/46/35556?source=related_link\">",
"      Brimonidine and timolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_63_8184="Approach to minimal bright red bleeding per rectum";
var content_f7_63_8184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to minimal bright red bleeding per rectum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8184/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8184/contributors\">",
"     Robert M Penner, BSc, MD, FRCPC, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8184/contributors\">",
"     Sumit R Majumdar, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8184/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8184/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8184/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/63/8184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal passage of minimal bright red blood most commonly occurs in a chronic intermittent pattern and has also been referred to as \"scant hematochezia\" or \"scant rectal bleeding\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/1\">",
"     1",
"    </a>",
"    ]. Although we are unaware of any standardized definition, in this review we use the term minimal bright red bleeding per rectum (BRBPR) to indicate such patient complaints as small amounts of red blood on toilet paper after wiping or a few drops of blood in the toilet bowl after defecation. Small amounts of blood on the surface of the stool is also considered minimal BRBPR, but red blood intermixed with stool is not.",
"   </p>",
"   <p>",
"    Benign etiologies are common, and there are few recommendations on the appropriate evaluation of patients with minimal BRBPR. This topic reviews the evidence for evaluating such patients and makes recommendations for evaluation based on age and other risk factors for more serious etiologies of minimal BRBPR. The approach to patients who pass larger amounts of blood or blood intermixed with stool is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCOPE OF THE PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;By self-report, minimal BRBPR occurs in approximately 15 percent of people [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The problem may be even more common in younger adults because of under-reporting to physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. This latter point was illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 202 community-dwelling adults ages 30 and older in Australia found that 14 percent reported seeing blood on the toilet paper and two percent reported seeing blood in the toilet bowl [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/2\">",
"       2",
"      </a>",
"      ]. However, 43 percent of the people seldom or never looked at either their stool or the toilet paper, suggesting that the true frequencies are higher.",
"     </li>",
"     <li>",
"      A community-based study of 1643 adults ages 20 to 64 found that 13 percent reported blood on wiping [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/3\">",
"       3",
"      </a>",
"      ]. The prevalence of any rectal bleeding was significantly higher in younger people. Only 14 percent of those with any rectal bleeding had seen a physician for bowel problems in the prior year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The etiology of bleeding is highly variable and depends upon the nature of the population studied. The etiology of minimal BRBPR is often difficult to determine because individual patients may have multiple potentially culpable lesions found at endoscopy. Only when a lesion is witnessed to be actively bleeding can it be definitively considered the cause of bleeding. In addition, colorectal neoplasms (mostly adenomas) have been found in 16 percent of patients who were concurrently diagnosed with an anorectal source of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common causes of minimal BRBPR are discussed below (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Differential diagnosis'",
"    </a>",
"    below). Hemorrhoids are present in anywhere from 27 to 95 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Diverticulosis is a common finding on endoscopy in the elderly, but is generally an incidental finding in the workup of chronic minimal BRBPR, since diverticular bleeding is usually more acute and of greater volume [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scant rectal bleeding is also a common presenting symptom of more sinister diagnoses, such as colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]. However, benign anorectal pathologies appear to account for 90 percent or more of all episodes of minimal BRBPR. The true proportion of benign etiologies may be even higher since many young people with minimal BRBPR never present for care. The appropriate evaluation of a patient presenting with minimal BRBPR must be guided by the risk of underlying serious pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common causes and presentations of minimal BRBPR include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhoids &mdash; Painless bleeding is usually associated with a bowel movement. Bright red blood typically coats the stool at the end of defecation. Blood may also drip into the toilet or stain toilet paper. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=see_link\">",
"       \"Overview of hemorrhoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anal fissures &mdash; Anal fissures can usually be diagnosed from the history. Affected patients describe a tearing pain with the passage of bowel movements. The passage of stool may be accompanied by bright rectal bleeding usually limited to a small amount on the toilet paper or on the surface of stool. Some patients complain of an itch or perianal skin irritation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"       \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polyps &mdash; Polyps, including adenomatous polyps, are generally asymptomatic and are most often detected by colon cancer screening tests. Small adenomas do not typically bleed, but occult bleeding and minimal BRBPR can occur; minimal BRBPR is more likely with distal polyps. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"       \"Approach to the patient with colonic polyps\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proctitis &mdash; Patients with proctitis or proctosigmoiditis often present insidiously with intermittent rectal bleeding associated with the passage of mucus, and mild diarrhea with fewer than four small loose stools per day. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"       \"Management of mild to moderate ulcerative colitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rectal ulcers &mdash; Rectal ulcers can present with bleeding, passage of mucus, straining during defecation, and a sense of incomplete evacuation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21125?source=see_link\">",
"       \"Solitary rectal ulcer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cancer &mdash; The majority of patients with symptomatic colorectal cancer have hematochezia, abdominal pain,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a change in bowel habits (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"      </a>",
"      ). Patients with minimal BRBPR from colorectal cancer are likely to have left-sided lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the clinical assessment is to identify patients who are at high enough risk for a serious cause of bleeding that the presentation with minimal BRBPR requires additional testing.",
"   </p>",
"   <p>",
"    Even careful clinical assessment can be unreliable both for determining the site of bleeding and for ruling out significant pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/6-8,13-15\">",
"     6-8,13-15",
"    </a>",
"    ]. As an example, the presence of hemorrhoids does not exclude a more proximal culprit lesion, and could even mask the concomitant bleeding of an early neoplastic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/13\">",
"     13",
"    </a>",
"    ]. A study of 145 patients ages 40 and older who had rectal bleeding of less than six months duration found that 11 of the 63 patients who the primary care provider had predicted an anal source of pathology had a colonic or rectal source [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The difficulties in clinical assessment were further illustrated in a study of primary care patients that identified 297 people who reported visible rectal bleeding on a review of systems questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/6\">",
"     6",
"    </a>",
"    ]. Of these patients, 201 underwent evaluation with sigmoidoscopy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema, and 48 (24 percent) were found to have serious pathology including 26 with polyps, 9 with inflammatory bowel disease (IBD), and 13 with colon cancer. Of the patients with serious pathology, 96 percent reported blood on the toilet paper and 81 percent that blood colored the toilet water; however, the study did not report the frequency of serious pathology in patients who had just these symptoms. Among the 58 patients younger than 50 years, there were no cases of cancer, but 12 percent had polyps or IBD. Despite evaluating a number of clinical variables and anoscopic findings, it was not possible to identify a group of 15 or more patients whose risk of serious conditions was lower than 7 percent. Only older age, shorter duration of bleeding, and blood mixed with stool were associated with a serious cause of rectal bleeding.",
"   </p>",
"   <p>",
"    One retrospective study of 223 adult patients younger than 50 years with nonurgent rectal bleeding found that four (2 percent) had colon cancer and 22 (10 percent) had adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/16\">",
"     16",
"    </a>",
"    ]. However, this study was in a group of patients who were referred for colonoscopy because of bleeding and included patients who had more than just minimal BRBPR. Thus, the prevalence of severe pathology was likely higher than would be found in an unselected group of young patients with minimal BRBPR [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/17\">",
"     17",
"    </a>",
"    ]. Similarly, in a study of 265 patients in a primary care practice with new-onset rectal bleeding (not just minimal BRBPR), among 51 patients ages 45 to 54 there were two (4 percent) colorectal cancers and no adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients presenting with scant rectal bleeding will already have indications for colon cancer screening by colonoscopy but will not have been investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. All of these patients can be recommended for further evaluation for screening purposes alone. In the remaining patients the history and physical examination, in combination with risk assessment for serious pathology based predominantly on age, can be used to guide the need for additional testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should be directed at confirming the diagnosis of scant rectal bleeding and at identifying potentially worrisome symptoms and historical risk factors.",
"   </p>",
"   <p>",
"    A history of minimal BRBPR suggests a lesion near the anal canal, but it must be differentiated from a history of melena (which implies upper GI or slow proximal colonic bleeding) or maroon stool with intermixed bright red blood (which implies a source of proximal colonic or small intestinal bleeding). It should also be kept in mind that patients' and physicians' perceptions of stool color vary widely, even when assisted by a standardized color chart [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historical features that suggest an anorectal source include spots of blood seen on the toilet paper or blood dripping into the toilet after defecation. This pattern has been referred to as \"outlet-type bleeding\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anal pain during or after defecation is usually due to anal fissures, but can also be present with rectal carcinoma (as well as infectious causes such as herpes) and so is not helpful in distinguishing benign from more serious etiologies. A history of recent rectal trauma from medical procedures like transrectal prostate biopsy or from anal receptive intercourse may suggest an obvious source of blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic symptoms such as night sweats, fever, or weight loss suggest malignancy or chronic infection or inflammation; diarrhea preceding or accompanying passage of blood suggests colitis; tenesmus can be present with proctitis; and non-specific abdominal pain indicates a process that may include, but is not limited to, the rectum. Lastly, change in the frequency or caliber of stools is a historical feature suggestive of colonic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/25\">",
"     25",
"    </a>",
"    ]. The presence of any of these symptoms suggests that further evaluation should be performed.",
"   </p>",
"   <p>",
"    Past medical history should consider previous gastrointestinal blood loss and investigations, as well as previously resected colon cancer or polyps. A history of inflammatory bowel disease is important because these patients (after about eight years of disease) are at increased risk of colonic neoplasm. A history of pelvic radiation therapy is noteworthy because radiation proctitis has been known to occur two to three years after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Age is a major risk factor for colorectal cancer. It is a rare diagnosis before the age of 40; the incidence begins to increase significantly between the ages of 40 and 50, and age-specific incidence rates increase in each succeeding decade thereafter (",
"    <a class=\"graphic graphic_figure graphicRef71126 \" href=\"UTD.htm?15/63/16381\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A family history should be taken in detail to further stratify colorectal cancer risk, and it should include not only a history of confirmed colorectal cancers, but also a history of family members known to have colonic polyps or other malignancies that could be associated with familial colon cancer syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should be directed at identifying possible or definite sources of bleeding and at finding worrisome distal lesions that may be detectable on examination. A detailed physical examination must include external inspection of the anus and a digital rectal examination. Having the patient bear down during the examination may induce prolapse of a hemorrhoid or bleeding of a surface lesion. If frank blood is not seen, fecal occult blood testing should be performed since a positive test would suggest a need for further investigation; a negative fecal occult blood test is not helpful.",
"   </p>",
"   <p>",
"    When available, office-based anoscopy or proctoscopy should be carried out in patients who present with acute minimal BRBPR because these are simple maneuvers that do not require bowel preparation, and because the yield of these tests is highest when performed during a bleeding episode. In fact, anoscopy has a higher sensitivity for the detection of hemorrhoids than flexible video endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing contributes little and is not routinely recommended, but if it is performed and anemia or iron deficiency are discovered, these are indications for additional investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy or sigmoidoscopy are generally recommended when additional evaluation beyond the history and physical examination is warranted.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema has no role in the initial evaluation of minimal BRBPR as it is insensitive to small neoplasms, cannot identify acutely bleeding lesions, and does not evaluate the distal colon and rectum well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sigmoidoscopy versus colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible sigmoidoscopy investigates the distal 60 cm of the colon (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    ). It has the advantages over colonoscopy that it can be done without sedation (although sedation is sometimes used for the procedure) and is available in most centers. The main disadvantage of sigmoidoscopy is the potential need for a colonoscopy if a source of bleeding is not found or if a distal adenomatous polyp is found, thus exposing the patient to two endoscopic procedures.",
"   </p>",
"   <p>",
"    Colonoscopy is the definitive tool for evaluating the entire colon for neoplastic lesions and is also a sensitive tool for the detection of all other bleeding lesions in the lower GI tract (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    ). Colonoscopy requires full bowel preparation and a facility where the test is available. It is usually performed under conscious sedation.",
"   </p>",
"   <p>",
"    Proponents of colonoscopy to evaluate scant rectal bleeding have cited concerns that patients may have proximal lesions that are out of the reach of the sigmoidoscope. Most studies that reported a high incidence of proximal neoplasms in patients with scant BRBPR have lacked detailed descriptions of the bleeding pattern and were either uncontrolled or reported retrospective data [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/6,7,15,21,27,28\">",
"     6,7,15,21,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, other studies have found that sigmoidoscopy is a sufficient initial test for many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/23,25,29\">",
"     23,25,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of the largest prospective studies that looked specifically at patients with scant BRBPR, structured interviews of 4265 patients referred for colonoscopy found that 468 patients had scant BRBPR, 299 had occult rectal bleeding, and 57 reported dark red rectal bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients were excluded if they had inflammatory bowel disease or a personal or family history of colorectal cancer. Colonic neoplasms were found in 18 percent of patients with minimal BRBPR and in 7.5 percent of controls. However, the majority of these lesions were within reach of a sigmoidoscope and patients with minimal BRBPR were at no increased risk for proximal lesions compared with controls. Among 89 patients who were age 40 years or younger, there were three cancers and five adenomas; no cancers and only two adenomas were found proximal to the reach of a sigmoidoscope. By comparison, the risk of proximal neoplasms was significantly increased in patients with either occult bleeding (odds ratio [OR] 3.1. 95% CI 1.8-5.5) or maroon colored blood in their stool (OR 4.8, 95% CI 2.0-11.5).",
"     </li>",
"     <li>",
"      Similarly, a smaller study that included 115 patients with \"outlet bleeding\" (defined as bright red blood seen during or after defecation, on the toilet paper or in the toilet bowl) and no other symptoms or risk factors for colon cancer found that only one adenomatous polyp and no cancers would have been missed by sigmoidoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study discussed above of 223 adult patients younger than 50 years referred for colonoscopy for nonurgent rectal bleeding (some of which was more than minimal BRBPR), four cancers and 22 adenomas were detected [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/16\">",
"       16",
"      </a>",
"      ]. The only lesions found proximal to the reach of a sigmoidoscope were six adenomas smaller than 8 mm in size.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to concerns about missing proximal lesions, one study found that sigmoidoscopy as an initial investigation of patients with bright red hematochezia was not cost-effective because it so often had to be followed with colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/21\">",
"     21",
"    </a>",
"    ]. However, that study excluded patients with histories suggestive of outlet bleeding. A study of outcomes after clinicians selected what they believed to be the \"best\" test for patients presenting to hospitals with hematochezia found that colonoscopy identified a diagnosis in 90 percent of patients, but sigmoidoscopy yielded a conclusive diagnosis in fewer than 10 percent; although 69 percent of sigmoidoscopies were abnormal, further tests were required in 90 percent of the hospitalized patients who underwent sigmoidoscopy as their first investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sigmoidoscopy is recommended as a first investigation for bright red hematochezia by some authors for patients up to age 50 to 55 years, and it is acknowledged as an acceptable alternative for colorectal cancer screening alone or in combination with double contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/19,25\">",
"     19,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Society for Gastrointestinal Endoscopy recommends colonoscopy in all patients for whom an anorectal source of bleeding is not found at initial evaluation. These guidelines further suggest, \"middle-aged and older individuals may need further investigation even in the presence of an anal lesion\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/1\">",
"     1",
"    </a>",
"    ]. These are the only consensus recommendations, to our knowledge, that specifically address scant rectal bleeding, but other recommendations on lower GI bleeding may be applied to this setting. As an example, The European Panel on Appropriateness of Gastrointestinal Endoscopy suggests that colonoscopy is inappropriate in patients under 50 years of age with an identified source of bleeding, but it is generally appropriate in patients with no identified source of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since most authors agree that colonoscopy is the test of first choice in patients over 50 to 55 years of age, and given that the American Gastroenterological Association and US Multisociety Task Force on Colorectal Cancer recommendations for colon cancer screening in patients with \"average risk\" also begin at age 50 years, we believe that patients over 50 years of age with scant rectal bleeding should undergo colonoscopy regardless of the presence or absence of identified anorectal pathology. In patients approaching 50 years of age, colonoscopy may be reasonable when no anorectal source of bleeding has been found. This age group is at lower risk of colorectal cancer but does have a significant incidence of precancerous adenomatous polyps. One study of screening colonoscopy in 906 patients aged 40 to 49 years, for example, found no cancers, but adenomatous polyps in about 13 percent of those examined; 3.5 percent had advanced lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We consider flexible sigmoidoscopy to be an alternative first line of investigation in patients with unexplained bleeding up to the age of 50 years; the choice of test in this group may be influenced by cost and availability of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       \"Patient information: Colonoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=see_link\">",
"       \"Patient information: Bloody stools (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"       \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/10/17569?source=see_link\">",
"       \"Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few studies that have addressed issues relevant to the appropriate evaluation of patients with minimal bright red bleeding per rectum (BRBPR). The following recommendations represent a combination of extrapolation from existing studies, most of which have not been performed in patients with strictly minimal BRBPR, and expert opinion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Red flags",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with minimal BRBPR in the following categories should undergo additional testing regardless of age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of melena, dark red blood per rectum, or postural vital sign abnormalities should be evaluated for upper gastrointestinal tract pathology first. Even if a lower GI tract source is considered possible, these patients are more likely to have proximal rather than distal colonic lesions and should undergo colonoscopy after upper GI tract investigations.",
"     </li>",
"     <li>",
"      Patients with symptoms suggestive of malignancy such as constitutional symptoms, anemia, or change in frequency, caliber or consistency of stools, should undergo colonoscopy.",
"     </li>",
"     <li>",
"      Patients with fecal occult blood positive stools are known to derive mortality benefit from investigation with colonoscopy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link\">",
"       \"Evaluation of occult gastrointestinal bleeding\"",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. Hemorrhoids do not affect the prevalence of positive occult blood tests [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with family histories suggestive of familial polyposis or hereditary nonpolyposis colon cancer syndromes who present with bleeding per rectum should be investigated with colonoscopy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with minimal BRBPR who were felt not to require initial colonoscopy or sigmoidoscopy who then develop new constitutional symptoms or a change in bowel habits should undergo colonoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Age 50 or older",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most authors agree that colonoscopy is the test of first choice in patients over 50 to 55 years of age. In addition, the American Gastroenterological Association and the United States Multisociety Task Force on Colorectal Cancer recommend that colon cancer screening in patients with \"average risk\" begin at age 50 years. For these reasons, we believe that patients over 50 years of age with scant rectal bleeding should undergo colonoscopy regardless of the presence or absence of identified anorectal pathology on clinical examination.",
"   </p>",
"   <p>",
"    Patients who have had a technically adequate normal colonoscopy within the previous two to three years have had insufficient time to develop a clinically important neoplasm, and more limited investigations can be considered. Care should be taken, however, to ensure that the prior colonoscopy reached the cecum with good visualization of all colonic anatomy. Ideally, in order to consider the prior study technically adequate, it should be documented that the terminal ileum was reached and the bowel preparation was satisfactory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ages 40 to 50",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with minimal BRBPR who are aged 40 to 50 and who do not appear to be at increased risk for colorectal cancer based on their presentation and history should undergo at least a sigmoidoscopy (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Sigmoidoscopy versus colonoscopy'",
"    </a>",
"    above). Colonoscopy should be considered if no source of bleeding is identified on sigmoidoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Age less than 40",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with minimal BRBPR younger than 40 years are at low risk of colorectal cancer (",
"    <a class=\"graphic graphic_figure graphicRef71126 \" href=\"UTD.htm?15/63/16381\">",
"     figure 1",
"    </a>",
"    ). Thus, further evaluation is not necessary, if the presentation and history do not suggest an increased risk of cancer and a potential source of bleeding (such as hemorrhoids or an anal fissure) is identified on physical examination or",
"    <span class=\"nowrap\">",
"     anoscopy/proctoscopy.",
"    </span>",
"    If no potential source is identified, such patients should undergo sigmoidoscopy or perhaps colonoscopy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Sigmoidoscopy versus colonoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Persistent bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent passage of minimal BRBPR may require management somewhat different from that described above. The American Society for Gastrointestinal Endoscopy recommends that patients with persistent or recurrent bleeding undergo a more thorough evaluation, if colonoscopy or x-rays were not performed initially [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/1\">",
"     1",
"    </a>",
"    ]. However, some studies have suggested that a longer duration of bleeding is associated with a",
"    <strong>",
"     lower",
"    </strong>",
"    risk of cancer. In one study of patients with rectal bleeding, for example, the risk of cancer was higher among patients older than age 50 when bleeding had been present for less than two months (18 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8184/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of definitive data or expert consensus, and given the possibility that a patient who has hemorrhoids or an anal fissure could also develop more serious pathology, we recommend a cautious strategy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who continue to pass blood after the identification and definitive management of an anorectal lesion should generally undergo colonoscopy at least once during their workup to ensure that an additional or concurrent proximal lesion has not been missed.",
"     </li>",
"     <li>",
"      Patients with recurrent minimal BRBPR should be periodically reassessed for any change in symptoms or any development of new \"red flags\" (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Red flags'",
"      </a>",
"      above) that would require additional investigation.",
"     </li>",
"     <li>",
"      Patients over the age of 50 who have recurrent minimal BRBPR should undergo colonoscopy every three to five years.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/1\">",
"      The role of endoscopy in the patient with lower gastrointestinal bleeding. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1998; 48:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/2\">",
"      Dent OF, Goulston KJ, Zubrzycki J, Chapuis PH. Bowel symptoms in an apparently well population. Dis Colon Rectum 1986; 29:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/3\">",
"      Talley NJ, Jones M. Self-reported rectal bleeding in a United States community: prevalence, risk factors, and health care seeking. Am J Gastroenterol 1998; 93:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/4\">",
"      Eslick GD, Kalantar JS, Talley NJ. Rectal bleeding: epidemiology, associated risk factors, and health care seeking behaviour: a population-based study. Colorectal Dis 2009; 11:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/5\">",
"      Goulston K, Chapuis P, Dent O, Bokey L. Significance of bowel symptoms. Med J Aust 1987; 146:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/6\">",
"      Helfand M, Marton KI, Zimmer-Gembeck MJ, Sox HC Jr. History of visible rectal bleeding in a primary care population. Initial assessment and 10-year follow-up. JAMA 1997; 277:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/7\">",
"      Goulston KJ, Cook I, Dent OF. How important is rectal bleeding in the diagnosis of bowel cancer and polyps? Lancet 1986; 2:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/8\">",
"      Segal WN, Greenberg PD, Rockey DC, et al. The outpatient evaluation of hematochezia. Am J Gastroenterol 1998; 93:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/9\">",
"      Korkis AM, McDougall CJ. Rectal bleeding in patients less than 50 years of age. Dig Dis Sci 1995; 40:1520.",
"     </a>",
"    </li>",
"    <li>",
"     Simmang CL, Shires GT. Diverticular disease of the colon. In: Sleisenger and Fordtran's Gastrointestinal and liver disease: pathophysiology, diagnosis, management, 7th ed, Feldman M, Friedman LS, Sleisenger MH (Eds), Saunders, Philadelphia 2002. p.2100.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/11\">",
"      Speights VO, Johnson MW, Stoltenberg PH, et al. Colorectal cancer: current trends in initial clinical manifestations. South Med J 1991; 84:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/12\">",
"      Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 1999; 94:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/13\">",
"      Bat L, Pines A, Rabau M, et al. Colonoscopic findings in patients with hemorrhoids, rectal bleeding and normal rectoscopy. Isr J Med Sci 1985; 21:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/14\">",
"      Mant A, Bokey EL, Chapuis PH, et al. Rectal bleeding. Do other symptoms aid in diagnosis? Dis Colon Rectum 1989; 32:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/15\">",
"      Graham DJ, Pritchard TJ, Bloom AD. Colonoscopy for intermittent rectal bleeding: impact on patient management. J Surg Res 1993; 54:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/16\">",
"      Wong RF, Khosla R, Moore JH, Kuwada SK. Consider colonoscopy for young patients with hematochezia. J Fam Pract 2004; 53:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/17\">",
"      Alonso-Coello P, Wong RF, Kuwada SK. Other strategies for evaluating rectal bleeding in younger patients. J Fam Pract 2005; 54:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/18\">",
"      du Toit J, Hamilton W, Barraclough K. Risk in primary care of colorectal cancer from new onset rectal bleeding: 10 year prospective study. BMJ 2006; 333:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/19\">",
"      Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/20\">",
"      Mitka M. Colon cancer screening guidelines stress initial test's importance. JAMA 2003; 289:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/21\">",
"      Fine KD, Nelson AC, Ellington RT, Mossburg A. Comparison of the color of fecal blood with the anatomical location of gastrointestinal bleeding lesions: potential misdiagnosis using only flexible sigmoidoscopy for bright red blood per rectum. Am J Gastroenterol 1999; 94:3202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/22\">",
"      Zuckerman GR, Trellis DR, Sherman TM, Clouse RE. An objective measure of stool color for differentiating upper from lower gastrointestinal bleeding. Dig Dis Sci 1995; 40:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/23\">",
"      Church JM. Analysis of the colonoscopic findings in patients with rectal bleeding according to the pattern of their presenting symptoms. Dis Colon Rectum 1991; 34:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/24\">",
"      Kinney TP, Kozarek RA, Ylvisaker JT, et al. Endoscopic evaluation and treatment of rectal hemorrhage after prostate biopsy. Gastrointest Endosc 2001; 53:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/25\">",
"      Van Rosendaal GM, Sutherland LR, Verhoef MJ, et al. Defining the role of fiberoptic sigmoidoscopy in the investigation of patients presenting with bright red rectal bleeding. Am J Gastroenterol 2000; 95:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/26\">",
"      Teshima T, Hanks GE, Hanlon AL, et al. Rectal bleeding after conformal 3D treatment of prostate cancer: time to occurrence, response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys 1997; 39:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/27\">",
"      Swarbrick ET, Fevre DI, Hunt RH, et al. Colonoscopy for unexplained rectal bleeding. Br Med J 1978; 2:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/28\">",
"      Acosta JA, Fournier TK, Knutson CO, Ragland JJ. Colonoscopic evaluation of rectal bleeding in young adults. Am Surg 1994; 60:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/29\">",
"      Eckardt VF, Schmitt T, Kanzler G, et al. Does scant hematochezia necessitate the performance of total colonoscopy? Endoscopy 2002; 34:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/30\">",
"      Richter JM, Christensen MR, Kaplan LM, Nishioka NS. Effectiveness of current technology in the diagnosis and management of lower gastrointestinal hemorrhage. Gastrointest Endosc 1995; 41:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/31\">",
"      Gonvers JJ, De Bosset V, Froehlich F, et al. 8. Appropriateness of colonoscopy: hematochezia. Endoscopy 1999; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/32\">",
"      Imperiale TF, Wagner DR, Lin CY, et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002; 346:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/33\">",
"      Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/34\">",
"      Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8184/abstract/35\">",
"      Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6861 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8184=[""].join("\n");
var outline_f7_63_8184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCOPE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sigmoidoscopy versus colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Red flags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Age 50 or older",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ages 40 to 50",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Age less than 40",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Persistent bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6861\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6861|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/63/16381\" title=\"figure 1\">",
"      Age incidence CRC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=related_link\">",
"      Anal fissure: Clinical manifestations, diagnosis, prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=related_link\">",
"      Overview of hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/10/17569?source=related_link\">",
"      Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=related_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21125?source=related_link\">",
"      Solitary rectal ulcer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_63_8185="Gentamicin (systemic): Pediatric drug information";
var content_f7_63_8185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gentamicin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/47/761?source=see_link\">",
"    see \"Gentamicin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/8/18564?source=see_link\">",
"    see \"Gentamicin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8107079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8107109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gentamicin Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10481922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Aminoglycoside",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be based on actual weight unless the patient has hydrops fetalis. Dosage should be individualized based upon serum concentration monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General  dosing; susceptible infection:",
"     </b>",
"     I.V.: Extended-interval dosing strategies may vary by institution as a wide variety of dosing regimens have been studied. Consider single-dose administration with serum concentration monitoring in patients with urine output &lt;1 mL/kg/hour or serum creatinine &gt;1.3 mg/dL rather than scheduled dosing. Consider prolongation of dosing interval when coadministered with ibuprofen or indomethacin or in neonates with history of the following: Birth depression, birth hypoxia/asphyxia, or cyanotic congenital heart disease. Some dosing based on tobramycin studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Age-directed dosing",
"     </b>",
"     (de Hoog, 2002; DiCenzo, 2003; Hagen, 2009; Hansen, 2003; Ohler, 2000; Serane, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GA &lt;32 weeks: 4-5 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GA 32-36 weeks: 4-5 mg/kg/dose every 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GA &ge;37 weeks: 4-5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In some trials, a fixed interval of every 24 hours was used with dosages ranging from 2.5-4 mg/kg/dose based on GA (ie, lower doses were used for younger GA).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Weight-directed dosing",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &le;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt; 2 kg: 5 mg/kg/dose every 48 hours; in ELBW neonates (&lt;1 kg), the dosing interval may need extended through first 2 weeks of life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;2 kg: 4 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 8-28 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;2 kg: 4-5 mg/kg/dose every  24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;2 kg: 4 mg/kg/dose every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ECMO, initial dosing in full-term neonates:",
"     </b>",
"     I.V.: Initial dose: 2.5-3 mg/kg/dose every 18-24 hours; some experts recommend a higher initial dose of 5 mg/kg/dose; subsequent doses should be individualized by monitoring serum drug concentrations; when ECMO is discontinued, dosage may require readjustment due to large shifts in body water (Buck, 2003; Southgate, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CNS infection (VP-shunt infection, ventriculitis):",
"     </b>",
"     Limited information available: Intraventricular/intrathecal",
"     <b>",
"      (use a preservative free preparation)",
"     </b>",
"     : 1 mg/",
"     <b>",
"      day",
"     </b>",
"     (Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      NEC, prevention:",
"     </b>",
"     Limited data available; efficacy results variable: Oral: 2.5 mg/kg/dose every 6 hours beginning at birth and continued for 1 week was used in 22 neonates at high risk for the development of NEC (including prematurity, asphyxia, use of a UAC); results showed significant decrease in incidence of NEC with treatment group compared to placebo (Bury, 2001; Grylack, 1978); due to risk of resistant bacteria development, clinical benefits and risk with use should be evaluated prior to use.  Further studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10482944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/47/761?source=see_link\">",
"      see \"Gentamicin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be based on an estimate of ideal body weight. In morbidly obese children, adolescents, and adults, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW). Dosage should be individualized based upon serum concentration monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Some dosing is based on tobramycin studies:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conventional dosing: I.M., I.V.: 2.5 mg/kg/dose every 8 hours; some pediatric patients may require larger doses (ie, patients undergoing continuous hemofiltration, patients with major burns, febrile granulocytopenic patients); modify dose based on individual patient requirements as determined by renal function, serum drug concentrations, and patient-specific clinical parameters",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Manufacturer's recommendations: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants: 2.5 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children: 2-2.5 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended-interval dosing: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Weight-directed: 4.5-7.5 mg/kg/dose every 24 hours in patients with normal renal function (Contopoulos-Ioannidis, 2004;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Age-directed: Based on data from 114 patients, the following has been suggested (McDade, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     3 months to &lt;2 years: 9.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     2 to &lt;8 years: 8.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &ge;8 years: 7 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      CNS infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Meningitis (Tunkel, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants and Children: I.V.  7.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: I.V.: 5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     VP-shunt infection, ventriculitis: Limited data available: Intraventricular/intrathecal",
"     <b>",
"      (use a preservative free preparation)",
"     </b>",
"     (Tunkel, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &gt;3 months and Children: 1-2 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adults: 4-8 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cystic fibrosis, pulmonary infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conventional dosing: I.M., I.V.: 3.3 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended-interval dosing: I.V.: 10-12 mg/kg/dose every 24 hours (Flume, 2009; Van Meter, 2009);",
"     <b>",
"      Note:",
"     </b>",
"     The CF Foundation recommends extended-interval dosing as preferred over conventional dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Endocarditis, treatment:",
"     </b>",
"     I.M., I.V.: 3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided into 1-3 doses in combination with other antibiotics dependent upon organism and source of infection (ie, valve-type)  (Baddour, 2007; Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Intra-abdominal infection, complicated:",
"     </b>",
"     I.V.: 3-7.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8-24 hours (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Peritonitis (CAPD):",
"     </b>",
"     Intraperitoneal: Continuous: Loading dose: 8  mg per liter of dialysate; maintenance dose: 4 mg per liter (Warady, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      UTI:",
"     </b>",
"     Extended-interval dosing: I.V.: Based on data from 179 patients, the following age-directed dosing has been suggested (Carapetis, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1 month to &lt;5 years: 7.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5-10 years: 6 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;10 years: 4.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conventional: I.M., I.V.: 1-2.5 mg/kg/dose every 8-12 hours; to ensure adequate peak concentrations early in therapy, higher initial dosage may be considered in selected patients when extracellular water is increased (edema, septic shock, postsurgical, or trauma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Once daily: I.V.: 4-7 mg/kg/dose once daily; some clinicians recommend this approach for all patients with normal renal 	function; this dose is at least as efficacious with similar, if not less, toxicity than conventional dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants, Children, and Adolescents:  I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     The following adjustments have been recommended (Aronoff, 2007):",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on doses of   2.5 mg/kg/dose every 8 hours:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 12-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 48-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Intermittent hemodialysis: 2 mg/kg/dose; redose as indicated by serum concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Peritoneal dialysis (PD): 2 mg/kg/dose; redose as indicated by serum concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Continuous renal replacement therapy (CRRT):  2-2.5 mg/kg/dose every 12-24 hours, monitor serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Conventional dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: Administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-60 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-40 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Loading dose, then monitor concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     High-dose therapy: Interval may be extended (eg, every 48 hours) in patients with moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute) and/or adjusted based on serum concentration determinations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz, 2009): Dialyzable (~50%; variable; dependent on filter, duration, and type of IHD);",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Loading dose: 2-3 mg/kg loading dose followed by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">",
"     Mild UTI or synergy: 1 mg/kg every 48-72 hours; consider redosing for pre-HD or post-HD serum concentrations &lt;1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">",
"     Moderate to severe UTI: 1-1.5 mg/kg every 48-72 hours; consider redosing for pre-HD serum concentrations &lt;1.5-2 mcg/mL or post-HD concentrations &lt;1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">",
"     Systemic gram-negative rod infection: 1.5-2 mg/kg every 48-72 hours; consider redosing for pre-HD serum  concentrations &lt;3-5 mcg/mL or post-HD concentrations &lt;2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis (PD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Administration via PD fluid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Gram-positive infection (eg, synergy): 3-4 mg/L (3-4 mcg/mL) of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Gram-negative infection: 4-8 mg/L (4-8 mcg/mL) of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Administration via I.V., I.M. route during PD: Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute and follow serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVH/CVVHD/CVVHDF: Loading dose of 2-3 mg/kg followed by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Mild UTI or synergy: 1 mg/kg every 24-36 hours (redose when serum concentration &lt;1 mcg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Moderate to severe UTI: 1-1.5 mg/kg every 24-36 hours (redose when serum concentration &lt;1.5-2 mcg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Systemic gram-negative infection: 1.5-2.5 mg/kg every 24-48 hours (redose when serum concentration &lt;3-5 mcg/mL)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8107316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 60 mg (50 mL, 100 mL [DSC]); 80 mg (50 mL, 100 mL); 100 mg (50 mL, 100 mL); 120 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 40 mg/mL (2 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [pediatric]: 10 mg/mL (2 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [pediatric, preservative free]: 10 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8107117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10482973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Administer undiluted by deep I.M. route. Slower absorption and lower peak concentrations, probably due to poor circulation in the atrophic muscle, may occur following I.M. injection; in paralyzed patients, suggest I.V. route.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:  Administer by slow intermittent infusion over 30-60 minutes (administer higher doses over 60 minutes) or by direct injection over 15 minutes; final concentration for I.V. administration should not exceed 10 mg/mL; administer beta-lactams at least 1 hour before or after gentamicin; simultaneous administration may result in reduced antibacterial efficacy",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8107219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, mannitol 20%, LR, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with fat emulsion 10%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, alprostadil, amifostine, amiodarone, amsacrine, anidulafungin, atracurium, aztreonam, bivalirudin, caffeine citrate, caspofungin, cefepime, ceftazidime, ciprofloxacin, cisatracurium, cyclophosphamide, cyclosporine, cytarabine, daptomycin, dexmedetomidine, diltiazem, docetaxel, doripenem, doxapram, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, fludarabine, foscarnet, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, IL-2, insulin (regular), labetalol, levofloxacin, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, meropenem, midazolam, milrinone, morphine, multivitamins, nicardipine, ondansetron, oxytocin, paclitaxel, palonosetron, pancuronium, piperacillin/tazobactam, potassium chloride, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, theophylline, thiotepa, tigecycline, vasopressin, vecuronium, vinorelbine, vitamin B complex with C, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, azithromycin, drotrecogin alfa, furosemide, hetastarch in NS, idarubicin, indomethacin, iodipamide meglumine, pemetrexed, propofol, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Filgrastim, heparin, pantoprazole, phenytoin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, clindamycin, dimenhydrinate, iohexol, iopamidol, iothalamate meglumine 60%, penicillin G sodium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ampicillin, cloxacillin, heparin, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10482904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Premix solution: Do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10481923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of documented or suspected infections caused by susceptible gram-negative bacilli, including",
"     <i>",
"      Pseudomonas",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Proteus",
"     </i>",
"     ,",
"     <i>",
"      Serratia",
"     </i>",
"     , and gram-positive",
"     <i>",
"      Staphylococcus",
"     </i>",
"     (FDA approved in all ages); treatment of bone infections, CNS infections, respiratory tract infections, skin and soft tissue infections, as well as abdominal and urinary tract infections, endocarditis, and septicemia; used in combination with ampicillin as empiric therapy for sepsis in newborns",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8107082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Gentamicin may be confused with gentian violet, kanamycin, vancomycin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8107171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hyper/hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, depression, dizziness, drowsiness, encephalopathy, fever, headache, lethargy, pseudomotor cerebri, seizures, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema, itching, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite decreased,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea, enterocolitis, nausea, salivation increased, splenomegaly, stomatitis, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, eosinophilia, granulocytopenia, leukopenia, reticulocytes increased/decreased, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, LFTs increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions, pain at injection site, phlebitis/thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, gait instability, muscle cramps, muscle twitching, muscle weakness, myasthenia gravis-like syndrome, numbness, paresthesia, peripheral neuropathy, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing impairment, hearing loss (associated with persistently increased serum concentrations; early toxicity usually affects high-pitched sound), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, casts (hyaline, granular) in urine, creatinine clearance decreased, distal tubular dysfunction, Fanconi-like syndrome (high dose, prolonged course) (infants and adults), oliguria, renal failure (high trough serum concentrations), polyuria, proteinuria, serum creatinine increased, tubular necrosis, urine specific gravity decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, laryngeal edema, pulmonary fibrosis, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis, anaphylactoid reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10481924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gentamicin, any component, or other aminoglycosides",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10482248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing renal impairment; modify dosage in patients with renal impairment; monitor renal and eighth nerve function in patients with known or suspected renal impairment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use with caution in patients with auditory or vestibular impairment. Use with caution in patients with myasthenia gravis, hypocalcemia, and in conditions which depress neuromuscular transmission; may cause neuromuscular blockade and respiratory paralysis; risk increased with concomitant use of anesthesia or muscle relaxants. Use with caution in pediatric patients on extracorporeal membrane oxygenation (ECMO); pharmacokinetics of aminoglycosides may be altered; dosage adjustment and close monitoring necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid intramuscular administration in paralyzed patients, due to poor circulation in the atrophic muscles which may result in slower absorption and lower peak serum concentrations; use intravenous route. Oral use for the prevention of NEC in premature neonates may potentially increase risk for development of resistant bacteria; routine use is not recommended (Bury, 2001; Reber, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10481925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminoglycosides are associated with significant nephrotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Vestibular and permanent bilateral auditory ototoxicity can occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; tinnitus or vertigo are indications of vestibular injury and impending bilateral irreversible deafness; early ototoxicity usually affects high-pitched sound. Risk of nephrotoxicity and ototoxicity is increased in patients with impaired renal function, dehydration, high-dose therapy, or prolonged therapy. Peak and trough serum concentrations should be monitored periodically during therapy to assure adequate concentrations are achieved and to avoid potentially toxic levels",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Ototoxicity is associated with high serum concentrations persisting for prolonged periods; nephrotoxicity is associated with high serum trough concentrations. Risk of nephrotoxicity increases when used concurrently with other potentially nephrotoxic drugs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; renal damage is usually reversible. Risk of ototoxicity increases with use of potent diuretics",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Once-daily gentamicin administration has been associated with a pyrogenic endotoxin-like reaction (fever, chills, hypotension, tachycardia); some products contain sulfites which may cause allergic reactions in susceptible individuals. Not intended for long-term therapy due to toxic hazards associated with extended administration. Aminoglycosides can cause fetal harm when administered to a pregnant woman",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; aminoglycosides have been associated with several reports of total irreversible bilateral congenital deafness in pediatric patients exposed",
"     <i>",
"      in utero",
"     </i>",
"     . Hemodialysis can be used for overdose or toxic reactions",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     particularly if renal function decreased; peritoneal dialysis removal is less than hemodialysis; in neonates, may consider exchange transfusions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8107194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Alfa: Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Alfa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Beta: Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8107119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8107120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gentamicin crosses the placenta and produces detectable serum levels in the fetus. Renal toxicity has been described in two case reports following first trimester exposure. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy; therefore, the manufacturer classifies gentamicin as pregnancy category D. Although ototoxicity has not been reported following maternal use of gentamicin, a potential for harm exists.",
"     <b>",
"      [U.S. Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy induced physiologic changes, some pharmacokinetic parameters of gentamicin may be altered. Pregnant women have an average-to-larger volume of distribution which may result in lower serum peak levels than for the same dose in nonpregnant women. Serum half-life is also shorter.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10482974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Urinalysis, urine output, BUN, serum creatinine, peak and trough serum gentamicin concentrations, hearing test especially for those at risk for ototoxicity or who will be receiving prolonged therapy (&gt;2 weeks), CBC with differential",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     With conventional dosing, typically obtain serum concentration after the third dose; exceptions for earlier monitoring may include neonates or  patients with rapidly changing renal function. With extended-interval dosing, usually obtain serum concentration after first, second, or third dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Not all infants and children who receive aminoglycosides require monitoring of serum aminoglycoside concentrations. Indications for use of aminoglycoside serum concentration monitoring include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment course &gt;5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients with decreased or changing renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients with poor therapeutic response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates and Infants &lt;3 months of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Atypical body constituency (obesity, expanded extracellular fluid volume)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clinical need for higher doses or shorter intervals (eg, cystic fibrosis, burns, endocarditis, meningitis, critically ill patients, relatively resistant organism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients on hemodialysis or chronic ambulatory peritoneal dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Signs of nephrotoxicity or ototoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Concomitant use of other nephrotoxic agents",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10482975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Conventional dosing:",
"     </b>",
"     Timing of serum samples: Draw peak 30 minutes after 30-minute infusion has been completed or 1 hour following I.M. injection or beginning of infusion; draw trough immediately before next dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Therapeutic concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Serious infections: 6-8 mcg/mL (12-17 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Life-threatening infections: 8-10 mcg/mL (17-21 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Urinary tract infections: 4-6 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Synergy against gram-positive organisms: 3-5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Trough:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Serious infections: 0.5-1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Life-threatening infections: 1-2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     The American Thoracic Society (ATS) recommends trough levels of &lt;1 mcg/mL for adult patients with hospital-acquired pneumonia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Extended-interval:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Pediatric therapeutic monitoring protocols have not been standardized; peak values are 2-3 times greater with extended-interval dosing regimens compared to conventional dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Noncystic fibrosis patients: Consider monitoring serum concentration 18-20 hours after the start of the infusion to ensure the drug-free interval does not exceed typical postantibiotic effect (PAE) duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cystic fibrosis patients: Clinically two methods are utilized. Peak: 25-35 mcg/mL (some centers use 20-30 mcg/mL); 18- to 20-hour value: Detectable but &lt;1 mcg/mL; trough: Nondetectable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Method A: Obtain two serum concentrations at least 1 half-life apart after distribution is complete (eg, obtain a serum concentration 2 hours and 10 hours after the start of the infusion), calculate elimination rate and extrapolate a C",
"     <sub>",
"      max",
"     </sub>",
"     and C",
"     <sub>",
"      min",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Method B: Obtain a peak serum concentration 60 minutes after a 60-minute infusion and a serum concentration 18-20 hours after the start of the infusion to ensure the drug-free interval does not exceed typical postantibiotic effect (PAE) duration (4-6 hours)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10482905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits cellular initiation of bacterial protein synthesis by binding to 30S and 50S ribosomal subunits resulting in a defective bacterial cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13194938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Displays concentration-dependent killing; bacteriocidal",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10482906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Poorly absorbed (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intramuscular: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Primarily in the extracellular fluid volume and in most tissues; poor penetration into CSF; drug accumulates in the renal cortex; small amounts distribute into bile, sputum, saliva, and tears",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Higher in neonates than older pediatric patients; also increased in patients with edema, ascites, fluid overload; decreased in patients with dehydration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neonates: 0.45 &plusmn; 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: 0.4 &plusmn; 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 0.35 &plusmn; 0.15 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: 0.3 &plusmn; 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 0.2-0.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;1 week: 3-11.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1 week to 1 month: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 4 &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 2 &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents: 1.5 &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults with normal renal function: 1.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Anuria: 36-70 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Within 30-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 30 minutes after 30-minute infusion;",
"     <b>",
"      Note:",
"     </b>",
"     Distribution may be prolonged after larger doses. One study reported a 1.7-hour distribution period after a 60-minute, high-dose aminoglycoside infusion (Demczar, 1997).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Clearance is directly related to renal function; eliminated almost completely by glomerular filtration of unchanged drug with excretion into urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neonates: 0.045 &plusmn; 0.01 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: 0.1 &plusmn; 0.05 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 0.1 &plusmn; 0.03 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: 0.09 &plusmn; 0.03 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis: Dialyzable (50% to 100%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10482977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/8/18564?source=see_link\">",
"      see \"Gentamicin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink adequate amounts of water unless instructed to restrict fluid intake. May experience ringing in ears, dizziness, blurred vision, GI upset, loss of appetite, or photosensitivity. Report severe headache, changes in hearing acuity, ringing in ears, change in balance, changes in urine pattern, persistent diarrhea, respiratory difficulty, rash, fever, unhealed sores, sores in mouth, vaginal drainage, muscle or bone pain, change in gait, or worsening of condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F15573838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy in vivo, particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, \"Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):e394-434.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt-Mehta V, Johnson CE, and Schumacher RE, \"Gentamicin Pharmacokinetics in Term Neonates Receiving Extracorporeal Membrane Oxygenation,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1992, 12(1):28-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/1549536/pubmed\" id=\"1549536\" target=\"_blank\">",
"        1549536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, \"Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2003, 42(5):403-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/12739981/pubmed\" id=\"12739981\" target=\"_blank\">",
"        12739981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bury RG and Tudehope D, \"Enteral Antibiotics for Preventing Necrotizing Enterocolitis in Low Birthweight or Preterm Infants,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2001, (1):CD000405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/11279690/pubmed\" id=\"11279690\" target=\"_blank\">",
"        11279690",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carapetis JR, Jaquiery AL, Buttery JP, et al, \"Randomized, Controlled Trial Comparing Once Daily and Three Times Daily Gentamicin in Children With Urinary Tract Infections,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2001, 20(3):240-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/11303823/pubmed\" id=\"11303823\" target=\"_blank\">",
"        11303823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al, \"Extended-Interval Aminoglycoside Administration for Children: A Meta-Analysis,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(1):e111-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/15231982/pubmed\" id=\"15231982\" target=\"_blank\">",
"        15231982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Hoog M, Mouton JW, Schoemaker RC, et al, \"Extended-Interval Dosing of Tobramycin in Neonates: Implications for Therapeutic Drug Monitoring,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2002, 71(5):349-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/12011820/pubmed\" id=\"12011820\" target=\"_blank\">",
"        12011820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Demczar DJ, Nafziger AN, and Bertino JS Jr, \"Pharmacokinetics of Gentamicin at Traditional Versus High Doses: Implications for Once-Daily Aminoglycoside Dosing,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1997, 41(5):1115-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/9145878/pubmed\" id=\"9145878\" target=\"_blank\">",
"        9145878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiCenzo R, Forrest A, Slish JC, et al, \"A Gentamicin Pharmacokinetic Population Model and Once-Daily Dosing Algorithm for Neonates,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(5):585-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/12741432/pubmed\" id=\"12741432\" target=\"_blank\">",
"        12741432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flume PA, Mogayzel PJ Jr, Robinson KA, et al, \"Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2009, 180(9):802-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/19729669/pubmed\" id=\"19729669\" target=\"_blank\">",
"        19729669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilbert DN, \"Once-Daily Aminoglycoside Therapy,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(3):399-405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/2039189/pubmed\" id=\"2039189\" target=\"_blank\">",
"        2039189",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grylack LJ and Scanlon JW, \"Oral Gentamicin Therapy in the Prevention of Neonatal Necrotizing Enterocolitis. A Controlled Double-Blind Trial,\"",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1978, 132(12):1192-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/362900/pubmed\" id=\"362900\" target=\"_blank\">",
"        362900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hagen I and &Oslash;ymar K, \"Pharmacological Differences Between Once Daily and Twice Daily Gentamicin Dosage in Newborns With Suspected Sepsis,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2009, 31(1):18-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/18982422/pubmed\" id=\"18982422\" target=\"_blank\">",
"        18982422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hansen A, Forbes P, Arnold A, et al, \"Once-Daily Gentamicin Dosing for the Preterm and Term Newborn: Proposal for a Simple Regimen That Achieves Target Levels,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2003, 23(8):635-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/14647159/pubmed\" id=\"14647159\" target=\"_blank\">",
"        14647159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knoderer CA, Everett JA, and Buss WF, \"Clinical Issues Surrounding Once-Daily Aminoglycoside Dosing in Children,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):44-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/12523459/pubmed\" id=\"12523459\" target=\"_blank\">",
"        12523459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kraus DM, Pai MP, and Rodvold KA, \"Efficacy and Tolerability of Extended-Interval Aminoglycoside Administration in Pediatric Patients,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(7):469-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/12083974/pubmed\" id=\"12083974\" target=\"_blank\">",
"        12083974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):e18-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/21208910/pubmed\" id=\"21208910\" target=\"_blank\">",
"        21208910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDade EJ, Wagner JL, Moffett BS, et al, \"Once-Daily Gentamicin Dosing in Pediatric Patients Without Cystic Fibrosis,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(3):248-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/20180608/pubmed\" id=\"20180608\" target=\"_blank\">",
"        20180608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohler KH, Menke JA, and Fuller L, \"Use of Higher Dose Extended Interval Aminoglycosides in a Neonatal Intensive Care Unit,\"",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 2000, 17(6):285-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/11144309/pubmed\" id=\"11144309\" target=\"_blank\">",
"        11144309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, 808-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reimche LD, Rooney ME, Hindmarsh KW, et al, \"An Evaluation of Gentamicin Dosing According to Renal Function in Neonates With Suspected Sepsis,\"",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 1987, 4(3):262-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/3606761/pubmed\" id=\"3606761\" target=\"_blank\">",
"        3606761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serane TV, Zengeya S, Penford G, et al, \"Once Daily Dose Gentamicin in Neonates - Is Our Dosing Correct?\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2009, 98(7):1100-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/19397541/pubmed\" id=\"19397541\" target=\"_blank\">",
"        19397541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shevchuk YM and Taylor DM, \"Aminoglycoside Volume of Distribution in Pediatric Patients,\"",
"      <i>",
"       DICP",
"      </i>",
"      , 1990, 24(3):273-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/2316235/pubmed\" id=\"2316235\" target=\"_blank\">",
"        2316235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Southgate WM, DiPiro JT, and Robertson AF, \"Pharmacokinetics of Gentamicin in Neonates on Extracorporeal Membrane Oxygenation,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1989, 33(6):817-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/2764529/pubmed\" id=\"2764529\" target=\"_blank\">",
"        2764529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, \"Practice Guidelines for the Management of Bacterial Meningitis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van den Anker, JN, personal communication, June, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Meter DJ, Corriveau M, Ahern JW, et al, \"A Survey of Once-Daily Dosage Tobramycin Therapy in Patients With Cystic Fibrosis,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2009, 44(4):325-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/63/8185/abstract-text/19330772/pubmed\" id=\"19330772\" target=\"_blank\">",
"        19330772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Schaefer F, Holloway M, et al, \"Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2000, 20(6):610-24.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15997 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8185=[""].join("\n");
var outline_f7_63_8185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107079\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107109\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481922\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442576\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482944\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107316\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107117\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482973\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107219\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482904\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481923\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107082\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107171\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481924\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482248\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481925\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299397\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107194\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107119\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107120\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482974\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482975\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482905\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13194938\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482906\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482977\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15573838\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15997\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15997|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/21/3412?source=related_link\">",
"      Gentamicin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/23/28020?source=related_link\">",
"      Gentamicin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/36/37443?source=related_link\">",
"      Gentamicin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/47/761?source=related_link\">",
"      Gentamicin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/8/18564?source=related_link\">",
"      Gentamicin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/46/17123?source=related_link\">",
"      Gentamicin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/59/38835?source=related_link\">",
"      Gentamicin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/20/31042?source=related_link\">",
"      Gentamicin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_63_8186="Endoscopic stenting for malignant pancreaticobiliary obstruction";
var content_f7_63_8186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic stenting for malignant pancreaticobiliary obstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8186/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8186/contributors\">",
"     Douglas G Adler, MD, FACG, FASGE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8186/contributors\">",
"     Kathryn R. Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8186/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8186/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/63/8186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/63/8186/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/63/8186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1135516942\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary stents are used to relieve obstruction in patients with both benign and malignant disease. In the setting of malignant pancreaticobiliary obstruction, stents may be used as a bridge to surgery or, in patients with unresectable disease, for palliation.",
"   </p>",
"   <p>",
"    This topic will review the use of stents in the management of malignant pancreaticobiliary obstruction. The use of stents for the treatment of benign disease or for the prevention of post-endoscopic retrograde cholangiopancreatography induced pancreatitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=see_link&amp;anchor=H10#H10\">",
"     \"Endoscopic management of complications from laparoscopic cholecystectomy\", section on 'Endoscopic therapy for strictures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/51/826?source=see_link\">",
"     \"The role of endoscopy in biliary complications after liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of primary sclerosing cholangitis\", section on 'Endoscopic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922055\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the biliary tree, stents are commonly used to relieve obstruction due to primary pancreaticobiliary malignancy (resectable and unresectable), metastatic disease, and external biliary compression by lymph nodes. By providing biliary decompression, stenting can minimize the risk of developing cholangitis while relieving jaundice and pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922063\">",
"    <span class=\"h2\">",
"     Preoperative biliary drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distal placement of a plastic stent or a short self-expanding metal stent (SEMS) does not interfere with the ability to perform subsequent pancreaticoduodenectomy. However, the benefit of preoperative endoscopic biliary drainage with regard to postoperative outcomes in patients with resectable pancreaticobiliary disease is debated. Proceeding directly to surgery may limit the number of interventions and thus decrease costs and potential procedure-related complications. On the other hand, performing preoperative endoscopic biliary drainage may relieve jaundice and prevent complications due to cholestasis. In addition, preoperative stenting may allow time for neoadjuvant therapy in locally advanced pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Preoperative biliary decompression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link&amp;anchor=H16#H16\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\", section on 'Neoadjuvant therapy for potentially resectable tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preoperative metal stents appeared to be safe and effective in a multicenter retrospective study of 241 patients with pancreatic cancer who underwent preoperative metal stent placement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/1\">",
"     1",
"    </a>",
"    ]. The patients were followed for a mean duration of 6.3&nbsp;months, with 49 percent of patients being alive at 27 months. Successful stent placement was achieved in all patients and improved jaundice. Immediate complications included post-ERCP pancreatitis (n&nbsp;=&nbsp;14), stent migration (n&nbsp;=&nbsp;3), and duodenal perforation (n&nbsp;=&nbsp;3). Long-term complications included stent migration (n&nbsp;=&nbsp;9) and hepatic abscess (n&nbsp;=&nbsp;1). Fourteen patients (5.8&nbsp;percent) experienced stent occlusion, with a time to stent occlusion of 6.6 months (range 1 to 20 months). A total of 144 of 174 patients (83 percent) deemed to have resectable cancer at the time of diagnosis subsequently underwent curative surgery. Due to disease progression or the discovery of metastasis after neoadjuvant therapy, only 22 of 67 patients (33 percent) with borderline-resectable cancer underwent curative surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922070\">",
"    <span class=\"h2\">",
"     Palliation of unresectable cancer",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922460\">",
"    <span class=\"h3\">",
"     Obstruction of the distal bile duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal malignant biliary obstruction (ie, obstruction distal to the hilum) is often due to pancreatic cancer, cholangiocarcinoma, or external compression from lymph node metastases. Possible palliative treatments for unresectable malignant biliary obstruction include surgical bypass, percutaneous drainage, and endoscopic drainage with either plastic or metal biliary stents. A large meta-analysis reviewing 2436 patients comparing surgical bypass, endoscopic metal stents, and endoscopic plastic stents concluded that endoscopic metal stents are the treatment of choice in patients with unresectable distal malignant biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1135517012\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922078\">",
"    <span class=\"h3\">",
"     Obstruction at the hilum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hilar obstruction may result from cholangiocarcinoma (Klatskin tumor), gallbladder carcinoma, hepatoma, local extension of pancreatic cancer, solid metastases, or compression from lymph nodes. Endoscopic biliary drainage is the preferred treatment for palliative drainage in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/3\">",
"     3",
"    </a>",
"    ]. However, because it is technically difficult, endoscopic drainage of hilar obstructions should, in general, be performed by endoscopists with significant case volume and expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25802026\">",
"    <span class=\"h2\">",
"     Unknown resectability",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient's surgical plan may not be known during the initial endoscopic retrograde cholangiopancreatography (eg, if neoadjuvant chemotherapy is being considered or if biliary drainage is required before staging can be completed). Options in this setting include placing a plastic (and thus easily removed) stent or a SEMS (which provides longer-term patency, but in most cases cannot be removed). A Monte Carlo decision analysis compared several strategies in patients with obstructive jaundice from pancreatic cancer with an undetermined surgical plan, and the results suggested that a short-length SEMS is the preferred initial treatment for overall cost minimization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, the placement of metal stents should be considered in patients with potentially resectable pancreatic cancer, especially if surgery is likely to be delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135516949\">",
"    <span class=\"h1\">",
"     TYPES OF STENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922269\">",
"    <span class=\"h2\">",
"     Plastic stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plastic biliary stents have been used in benign and malignant biliary obstruction since their development during the 1980s (",
"    <a class=\"graphic graphic_picture graphicRef50266 \" href=\"UTD.htm?12/31/12784\">",
"     picture 1",
"    </a>",
"    ). Plastic stents can be made from multiple materials including Teflon, polyurethane, and polyethylene. Stent shapes include straight (Amsterdam), single-pigtail, and double-pigtail. Straight stents have one, two, or four flaps at each end to help anchor the stent. Available stent diameters include 7, 8.5, 10, and 11.5 Fr with lengths ranging between 5 and 15 cm. If longer stent lengths are needed, nasobiliary drains can be cut to a desired length, although they are prone to migration given the lack of flaps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135516956\">",
"    <span class=\"h2\">",
"     Metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-expanding metal stents (SEMS) have been used to treat malignant biliary strictures since the 1980s. SEMS can be uncovered, partially covered, or fully covered. The metal component can be stainless steel, nitinol (a combination of nickel and titanium), or Platinol&trade;. Platinol consists of a platinum core with nitinol encasement. Nitinol has traditionally been the preferred metal due to its ability to maintain the shape of a curved lumen, but there is no evidence that one material is superior in all situations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Covered stents can be lined with silicone, polycaprolactone, polyether polyurethane, polyurethane, or expanded polytetrafluoroethylene fluorinated ethylene propylene (PFTE). All are effective.",
"   </p>",
"   <p>",
"    Metal biliary stents are cylindrical in shape and made by interwoven alloy wires, with some stents having proximal and distal flaring to reduce migration (",
"    <a class=\"graphic graphic_picture graphicRef50214 \" href=\"UTD.htm?26/40/27264\">",
"     picture 2",
"    </a>",
"    ). Biliary SEMS are deployed with through-the-scope (TTS) delivery systems that have diameters ranging from 6 to 8.5 Fr. SEMS come pre-constrained within delivery catheters. Essentially, all currently available stents are deployed via the removal or withdrawal of an outer restraining sheath, although specific delivery catheter types and mechanisms vary widely. Some SEMS shorten upon deployment, which should be taken into consideration during selection of a stent length, during stent placement, and during stent deployment. After deployment, the stent material embeds into both the tumor and normal tissue by expansile, radial pressure. This process is necessary to keep the stent from migrating.",
"   </p>",
"   <p>",
"    Argon plasma coagulation can be used to trim SEMS that are malpositioned or that have migrated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7923076\">",
"    <span class=\"h3\">",
"     Available stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple stents are available in the United States and include (",
"    <a class=\"graphic graphic_table graphicRef71470 \" href=\"UTD.htm?3/49/3869\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      WallFlex stents (Boston Scientific) &ndash; Uncovered, partially covered, or fully covered Platinol stents. All WallFlex stents have deployment systems that allow the stent to be reconstrained and repositioned during deployment up to a predetermined \"point of no return,\" after which the stent must be deployed and cannot be reconstrained. Fully and partially covered WallFlex stents are lined with Permalume (silicone polymer membrane).",
"     </li>",
"     <li>",
"      Wallstent stents (Boston Scientific) &ndash; Uncovered or partially covered nitinol stents.",
"     </li>",
"     <li>",
"      Zilver stent (Cook Endoscopy) &ndash; Uncovered non-foreshortening nitinol stent.",
"     </li>",
"     <li>",
"      FLEXXUS stent (ConMed Corporation) &ndash; Uncovered non-foreshortening nitinol stent.",
"     </li>",
"     <li>",
"      ALIMAXX-B stent (MeritMedical Systems, Inc.) &ndash; Uncovered non-foreshortening nitinol stent.",
"     </li>",
"     <li>",
"      X-Suit NIR biliary stent (Olympus, Inc.) &ndash; Uncovered non-foreshortening nitinol stent.",
"     </li>",
"     <li>",
"      Viabil stent (The W.L. Gore &amp; Associates, Inc., marketed by ConMed Corporation) &ndash; Fully covered nitinol stent with a lining of expanded PFTE.",
"     </li>",
"     <li>",
"      Bonastent Biliary (EndoChoice, Inc.) &ndash; Uncovered foreshortening nitinol stent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metal biliary stents are available in 6, 8, and 10 mm diameters (18, 24, and 30 Fr, respectively). A large prospective study involving 241 patients with unresectable malignant biliary strictures randomized patients to a 6 mm Zilver stent, a 10 mm Zilver stent, or a 10 mm uncovered Wallstent to evaluate differences in occlusion rates between different diameter uncovered metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/9\">",
"     9",
"    </a>",
"    ]. Stent occlusions were much more common in the 6 mm group and were equivalent in the two 10 mm groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135516977\">",
"    <span class=\"h3\">",
"     Uncovered metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;An advantage of using uncovered metal stents is that they can be used anywhere in the biliary tree (including the hilum) (",
"    <a class=\"graphic graphic_picture graphicRef66141 \" href=\"UTD.htm?28/63/29681\">",
"     picture 3",
"    </a>",
"    ). In addition, multiple studies have demonstrated low rates of stent migration with uncovered metal stents in malignant biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. A prospective study involving 241 patients who received different types of uncovered metal stents for the treatment of unresectable malignant biliary strictures had only three cases of stent migration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/9\">",
"     9",
"    </a>",
"    ]. Another study of 101 patients who received an uncovered metal stent for malignant biliary obstruction did not have any cases of stent migration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disadvantages of uncovered metal stents include, at best, limited removability and higher rates of tumor ingrowth. Although tumor ingrowth is a significant problem and the most common cause of failure in uncovered stents, it is not a problem that is unique to this stent type, as tumor ingrowth can also occur in covered stents if the covering degrades or becomes compromised. (See",
"    <a class=\"local\" href=\"#H1135517074\">",
"     'Tissue ingrowth'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135516991\">",
"    <span class=\"h3\">",
"     Covered metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary advantages of covered stents are the potential reduction of tumor ingrowth and their potential for removability (",
"    <a class=\"graphic graphic_picture graphicRef77951 \" href=\"UTD.htm?21/10/21665\">",
"     picture 4",
"    </a>",
"    ). Rates of tumor ingrowth with covered metal stents have been examined in several trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study evaluated the patency of partially covered Wallstents in 48 patients as the primary treatment and in 56 patients as a reintervention for palliation of unresectable biliary obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/14\">",
"       14",
"      </a>",
"      ]. Stent occlusion occurred in a total of 19 patients. Etiologies included tumor overgrowth (ie, tumor blocking the ends of the stent), biliary sludge, and food impaction. Tumor ingrowth was not a cause of occlusion in any patient in this study.",
"     </li>",
"     <li>",
"      A prospective study with 80 consecutive patients who were treated with a partially covered Wallstent for distal malignant biliary obstruction had no stent failures thought to be secondary to tumor ingrowth [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study examined 101 consecutive patients with partially covered Wallstents for the treatment of malignant biliary strictures. Stent patency rates were 97 percent at three months, 85 percent at six months, and 68 percent at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/16\">",
"       16",
"      </a>",
"      ]. There were only three cases of stent occlusion, with no known stent failures secondary to tumor ingrowth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, studies directly comparing covered with uncovered stents have failed to show a benefit for covered stents with regard to stent patency. (See",
"    <a class=\"local\" href=\"#H7922550\">",
"     'Covered versus uncovered metal stents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Fully covered stents have the advantage of potential removability, but it must be noted that these devices do not have FDA approval for delayed removal. The fully covered WallFlex stent is approved for immediate removal in cases of misemployment.",
"   </p>",
"   <p>",
"    The disadvantages of using covered metal stents include potentially increased rates of stent migration, an inability to use the stents at the level of the hilum, and the possibility of stent-induced cholecystitis. Increased rates of stent migration are presumably secondary to the limited ability of the stents to embed into the tumor and surrounding tissue because of the overlying covering. Endoscopic sphincterotomy is commonly performed prior to placement of SEMS, in theory to help facilitate insertion and possibly minimize the risk of pancreatitis. However, performing biliary sphincterotomy prior to SEMS may lead to increased rates of stent migration and other complications. (See",
"    <a class=\"local\" href=\"#H1135517088\">",
"     'Migration'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1135517096\">",
"     'Cholecystitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17012685\">",
"    <span class=\"h2\">",
"     New developments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents that incorporate antitumor agents are being developed and evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In addition, there is interest in radioactive and biodegradable stents, but none are commercially available.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517012\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17012786\">",
"    <span class=\"h2\">",
"     Preoperative drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of preoperative endoscopic biliary drainage with regard to postoperative outcomes in patients with resectable pancreaticobiliary disease is debated. Proceeding directly to surgery may limit the number of interventions and thus decrease costs and potential procedure-related complications. On the other hand, performing preoperative endoscopic biliary drainage may relieve jaundice and prevent complications due to cholestasis. In addition, preoperative stenting may allow time for neoadjuvant therapy in locally advanced pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Preoperative biliary decompression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link&amp;anchor=H16#H16\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\", section on 'Neoadjuvant therapy for potentially resectable tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of preoperative endoscopic biliary drainage have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study was performed to evaluate the effect of preoperative biliary drainage on postoperative outcomes in 90 patients who underwent pancreaticoduodenectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/20\">",
"       20",
"      </a>",
"      ]. The majority of the patients had pancreatic cancer and 62 percent underwent preoperative biliary drainage, whereas 38 percent proceeded directly to surgery. Repeat surgery was required significantly more often in the group that went directly to surgery (4 versus 15 percent, p = 0.02). However, 30 and 90 day mortality rates were not significantly different.",
"     </li>",
"     <li>",
"      A multicenter randomized trial assigned 202 patients with resectable pancreatic cancer to four to six weeks of preoperative biliary drainage followed by surgery or to surgery alone within one week of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/21\">",
"       21",
"      </a>",
"      ]. While there were significantly more serious complications in the preoperative drainage group compared with the surgery alone group (74 versus 39 percent), mortality rates were not significantly different. However, it should be noted that the 25 percent initial endoscopic retrograde cholangiopancreatography (ERCP) failure rate in patients assigned to preoperative biliary drainage was much higher than what has been seen in other studies and in routine clinical practice. In addition, plastic stents were utilized instead of SEMS in all patients. Both of these factors could have contributed to the worse outcomes seen in the preoperative drainage group. In addition, no patients received neoadjuvant therapy. (See",
"      <a class=\"local\" href=\"#H17011425\">",
"       'Plastic versus metal stents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      SEMS placement in patients receiving neoadjuvant therapy for pancreatic cancer was examined in a series of 55 patients with biliary obstruction due to resectable or borderline resectable pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/22\">",
"       22",
"      </a>",
"      ]. The median time for the administration of neoadjuvant therapy and restaging was 104 days (range 70 to 260 days). Stent placement relieved the biliary obstruction in all patients. The presence of the short biliary stent did not interfere with surgery in the 27 patients who underwent pancreatoduodenectomy. By 260 days, stent occlusion had occurred in seven patients (13 percent) and stent migration in one patient (2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit in patients with hilar carcinoma is less clear. A meta-analysis of 11 studies addressed the benefit of preoperative biliary drainage in jaundiced patients with hilar cholangiocarcinoma (10 retrospective, only one prospective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/23\">",
"     23",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/24\">",
"     24",
"    </a>",
"    ]. There was no difference in death rate or length of postoperative stay with and without preoperative biliary decompression. However, overall postoperative and infectious complication rates were significantly adversely affected by preoperative biliary drainage compared with surgery without preoperative biliary drainage. Based on their results, the authors concluded that preoperative biliary decompression in jaundiced patients with hilar cholangiocarcinoma planned for surgery should not be routinely performed. Randomized trials with large sample size and optimal biliary drainage techniques are needed, although these have traditionally been difficult to perform given the small number of patients with cholangiocarcinoma who ultimately undergo surgery, as most present at an advanced state of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922765\">",
"    <span class=\"h2\">",
"     Distal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plastic biliary stents are commonly used as the initial endoscopic treatment for patients with malignant biliary obstruction. The placement of a plastic stent is inexpensive and effective, and the stent can be easily removed or exchanged. Plastic stents, however, eventually develop occlusion by sludge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacterial biofilm, and maintaining biliary drainage with plastic stents usually requires repeated ERCPs. Metal stents were introduced to help alleviate this problem by extending the duration of stent patency. However, metal stents have significantly higher costs and may not be removable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17011418\">",
"    <span class=\"h3\">",
"     Patency of plastic stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of function of plastic biliary stents remains highly variable, with stent patency typically ranging between 60 and 200 days. Studies looking at plastic stent function have demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial of 134 patients with malignant biliary strictures compared two types of straight plastic stents, 10 Fr Tannenbaum (Teflon) stents and 10 Fr Cotton-Leung (polyethylene) stents with side holes [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/25\">",
"       25",
"      </a>",
"      ]. There was no significant difference in the median duration of stent patency between the Teflon stent group and the polyethylene stent group (181 versus 133 days). In addition, there was no significant difference in median survival between the two groups.",
"     </li>",
"     <li>",
"      A prospective trial of 57 patients with distal unresectable malignant biliary strictures assigned patients to receive either a Tannenbaum biliary stent or a Cotton-Huibregtse (polyethylene) stent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/26\">",
"       26",
"      </a>",
"      ]. The median duration of stent patency was 96 days in the Teflon stent group and 76 days in the polyethylene stent group (p = 0.12). As in the previous study, there was no significant difference in length of survival between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether stent diameter influences outcomes has also been studied. A retrospective study of 63 patients compared 10 Fr stents with 11.5 Fr stents for the management of both malignant and benign biliary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/27\">",
"     27",
"    </a>",
"    ]. The study found no significant difference between the stents with regard to successful insertion rates, relief of jaundice, decline in total bilirubin, or complications. However, in practice, 11.5 Fr stents are rarely used over 10 Fr stents; 11.5 Fr stents are technically more cumbersome to place because of their increased diameter and do not provide any additional advantages over 10 Fr stents.",
"   </p>",
"   <p>",
"    There is no evidence to suggest that prophylactic antibiotics increase stent patency, though they may benefit patients with a history of cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\", section on 'Prophylactic antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17011425\">",
"    <span class=\"h3\">",
"     Plastic versus metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent patency for metal stents in general is longer than what is seen with plastic stents, with many studies showing mean or median patency rates of at least 270 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/12,29,30\">",
"     12,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis with 24 trials and 2436 patients compared surgical bypass, endoscopic metal stents, and endoscopic plastic stents in patients with unresectable malignant biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/2\">",
"     2",
"    </a>",
"    ]. Plastic stents had a lower risk of complications compared with surgical bypass (relative risk [RR] 0.6), but they had a higher risk of recurrent biliary obstruction (RR 18.6). Compared with plastic stents, metal stents had a lower risk of recurrent obstruction at four months (RR 0.4), but were not superior with regard to technical success, therapeutic success, mortality, or complications. There were no comparisons of metal stents with surgical bypass.",
"   </p>",
"   <p>",
"    Studies that have compared plastic and metal stents for the treatment of malignant biliary obstruction have found the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 105 patients were assigned to receive either a metal or a plastic biliary stent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/29\">",
"       29",
"      </a>",
"      ]. Median stent patency was significantly longer in the metal stent group compared with the plastic stent group (273 versus 126 days), with no significant differences in overall survival.",
"     </li>",
"     <li>",
"      A randomized trial of 118 patients assigned patients to plastic or metal stent placement and followed them for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/30\">",
"       30",
"      </a>",
"      ]. After one year, the occlusion rate was significantly higher in the plastic stent group compared with the metal stent group (70 versus 46 percent). Additionally, the number of days of hospitalization, duration of antibiotic treatment, and total number of ERCPs were all significantly higher in the plastic stent group (mostly due to the need for stent replacements).",
"     </li>",
"     <li>",
"      A retrospective study examined 112 patients who had received either a metal stent (covered or uncovered) or a plastic stent for unresectable malignant biliary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/12\">",
"       12",
"      </a>",
"      ]. Mean stent patency was significantly longer in patients who received metal stents compared with patients who received plastic stents (278 versus 133 days). Additionally, the incidence and length of hospitalization for cholangitis were significantly lower in the metal stent group, but there was no difference in mean total cost.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the available data, we suggest that patients with unresectable disease who are expected to survive more than three to six months be treated with metal stents. For a patient with a distal malignant biliary obstruction due to potentially resectable disease, the placement of a short distal metal stent should be considered, especially if surgery is likely to be delayed (eg, if neoadjuvant therapy is planned). Some surgeons prefer a plastic stent in this setting. It may be helpful to speak with the surgeon prior stent to placement, especially in complex cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Role of biliary drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cholangiocarcinoma or proximal malignant biliary strictures should only have metal stents placed once they have been formally deemed not to be surgical candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922550\">",
"    <span class=\"h3\">",
"     Covered versus uncovered metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have evaluated differences in stent patency rates between covered and uncovered metal stents for the treatment of distal malignant biliary disease. Individual trials have had variable results, with some showing increased patency rates for covered stents, whereas others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/10,11,31-35\">",
"     10,11,31-35",
"    </a>",
"    ]. A meta-analysis suggested longer stent patency with covered stents (weighted mean difference of 61 days, 95% confidence interval [CI] 26-95 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/36\">",
"     36",
"    </a>",
"    ]. However, a second meta-analysis found that there was no difference in stent patency at 6 and 12 months (odds ratio [OR] 1.8, 95% CI 0.63-5.3 and OR 1.3, 95% CI 0.65-2.4, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/37\">",
"     37",
"    </a>",
"    ]. There was also no difference in complications such as pancreatitis, cholecystitis, perforation, bleeding, or cholangitis or in the number of recurrent biliary obstructions. Covered stents had higher rates of migration (OR 7.1, 95% CI 2.3-22) and tumor overgrowth (OR 1.9, 95% CI 1.02-3.5) and lower rates of tumor ingrowth (OR 0.19, 95% CI 0.07-0.55).",
"   </p>",
"   <p>",
"    Two of the randomized trials that compared covered with uncovered stents found the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 129 patients with inoperable distal malignant biliary obstructions compared partially covered with uncovered stents [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/31\">",
"       31",
"      </a>",
"      ]. There was no difference between the partially covered and uncovered stents with regard to recurrent biliary obstruction (29 versus 18 percent, respectively). There was also no significant difference with regard to the median time to obstruction (357 versus 711 days) or median survival (227 versus 239 days). There was a higher rate of stent migration in the patients who had partially covered stents (12 versus 0 percent).",
"     </li>",
"     <li>",
"      A second trial with 400 patients also found no difference with regard to stent patency or survival [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/32\">",
"       32",
"      </a>",
"      ]. Stent failure rates were similar between those with covered and uncovered stents (24 versus 23 percent). The time it took for 25 percent of the stents to occlude did not significantly differ between those with covered and those with uncovered stents (154 versus 199 days). The median survival time was also similar (116 versus 174 days). Stent migration was more common in patients with covered stents (3 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, for the treatment of distal malignant biliary obstruction, we typically place uncovered metal stents in patients with an intact gallbladder because placement of a covered stent may block the cystic duct and lead to cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. However, cholecystitis can also be seen following placement of an uncovered stent, and whether use of a covered stent increases the risk of cholecystitis relative to that with an uncovered stent is unclear. As an example, in a study of 150 patients with an intact gallbladder, cholecystitis developed in 8 of 88 patients (9 percent) who received a covered stent and in 7 of 67 patients (10 percent) who received an uncovered stent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/38\">",
"     38",
"    </a>",
"    ]. Therefore, placement of a covered metal stent in a patient with an intact gallbladder is a reasonable alternative.",
"   </p>",
"   <p>",
"    For patients who have undergone prior cholecystectomy, the choice of covered versus uncovered stent is individualized given the location, geometry, and etiology of the stenosis. Patients with extrinsic compression may be adequately treated with an uncovered stent, while those with intraluminal tumors (especially papillary tumors) may benefit from a covered stent in an attempt to minimize tumor ingrowth. Of note, we avoid placing covered metal stents in proximal biliary strictures because placement of a covered stent in a patient with a proximal stricture could block the left or right hepatic duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7922596\">",
"    <span class=\"h2\">",
"     Hilar obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of malignant hilar obstruction is debated, though frequently these obstructions are treated with uncovered self-expanding metal stents (SEMS). Uncovered stents are used to avoid occluding drainage from the contralateral biliary system. Hilar obstruction from primary biliary tumors (ie, cholangiocarcinoma), secondary metastatic lesions, or extrinsic biliary compression from malignant adenopathy can all be treated with uncovered SEMS or plastic stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17011722\">",
"    <span class=\"h3\">",
"     Plastic versus metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that SEMS are preferable to plastic stents for the treatment of hilar tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 108 patients with unresectable complex hilar cholangiocarcinoma, patients were assigned to receive either a SEMS or a plastic stent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/46\">",
"       46",
"      </a>",
"      ]. Patients assigned to SEMS placement had a higher rate of successful drainage (70 verus 46 percent) and a significantly longer survival (126 versus 49 days).",
"     </li>",
"     <li>",
"      In a randomized trial of 20 patients, long term stent failure was higher in patients who received plastic stents compared with those who received SEMS (50 versus 18 percent), though the results did not reach statistical significance [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 62 patients, 28 patients received plastic stents and 34 received metal stents [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/43\">",
"       43",
"      </a>",
"      ]. Adverse outcomes (cholangitis, stent occlusion, stent migration, perforation, or the need for unplanned",
"      <span class=\"nowrap\">",
"       ERCP/percutaneous",
"      </span>",
"      transhepatic cholangiography) occurred significantly more frequently in patients who received plastic stents compared with patients who received metal stents (39 versus 12 percent, odds ratio 6.3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17011729\">",
"    <span class=\"h3\">",
"     Unilateral versus bilateral stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether to use unilateral or bilateral stents is debated. In many cases, unilateral stent placement will be adequate because only 25 to 30 percent of the liver needs to be drained to relieve jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/47\">",
"     47",
"    </a>",
"    ]. However, unilateral drainage alone may not relieve jaundice completely and may increase the risk of cholangitis.",
"   </p>",
"   <p>",
"    Studies comparing these approaches have reached variable conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early study of 70 patients, the use of two or more stents to achieve complete biliary drainage improved survival compared with one stent (176 versus 119 days), while reducing procedure-related mortality and cholangitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial, 157 patients were assigned to unilateral or bilateral hepatic drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/49\">",
"       49",
"      </a>",
"      ]. Stents were successfully placed in 70 of 79 patients (89 percent) assigned to receive unilateral stenting and in 60 of 78 patients (77 percent) assigned to receive bilateral stenting (p = 0.04). In a per-protocol analysis, there were no differences between the groups with regard to the rate of successful drainage, complications, and mortality. However, when an intention to treat analysis was carried out among the patients with successful stent placement, patients assigned to unilateral stent placement had higher rates of successful drainage (81 versus 73 percent). In addition, patients in the unilateral stent group had a lower incidence of early complications (19 versus 27 percent), in large part due to a lower rate of cholangitis (9 versus 17 percent).",
"     </li>",
"     <li>",
"      A retrospective study of 46 patients comparing treatment with unilateral SEMS (17 patients) versus bilateral SEMS (29 patients) showed improved cumulative stent patency in the bilateral group (median patency 210 days for unilateral stenting versus 488 days for bilateral stenting) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our practice is to place bilateral stents (plastic or metal) when possible in an attempt to maximize biliary drainage. Preprocedure computed tomography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance cholangiopancreatography imaging is often used in an attempt to identify the dominant biliary system in the event that only one side can be drained endoscopically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517058\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of biliary stent placement include stent occlusion and stent migration. Less common complications of biliary stent placement include cholecystitis, cholangitis, pancreatitis, perforation, and bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5508197\">",
"    <span class=\"h2\">",
"     Stent occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent occlusion is a common complication in patients with biliary stents for malignant obstruction. Stent occlusion may be secondary to tumor ingrowth, tumor overgrowth,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occlusion by sludge. In addition, regenerative changes can lead to nonmalignant tissue ingrowth or overgrowth. Patients with stent occlusion often present with elevated liver enzymes in a cholestatic pattern",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholangitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute cholangitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typically, endoscopic retrograde cholangiopancreatography (ERCP) is required to diagnose the cause of the occlusion. However, in one study with 26 patients, multidetector computed tomography (MDCT) was used to diagnose the cause of stent occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/51\">",
"     51",
"    </a>",
"    ]. For diagnosing tissue growth as the cause of obstruction, MDCT had a sensitivity of 87 percent and a specificity of 86 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517066\">",
"    <span class=\"h3\">",
"     Stent occlusion due to debris",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent occlusion is the most common cause of plastic biliary stent failure, with sludge being the primary etiology of occlusion. An analysis of clogged plastic stents using scanning electron microscopy revealed that the material clogging the stent adheres to the inner stent surface by numerous tiny threads [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one trial where the median patency of plastic stents was 126 days, the most common cause of plastic stent dysfunction was sludge deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients were retreated with plastic stents, and 48 percent of the second stents were clogged at the time of evaluation. The median stent patency for the second plastic stents was 80 days.",
"   </p>",
"   <p>",
"    Stent occlusion is also a common reason for the failure of metal biliary stents. Although smaller diameter stents (6 mm) occlude more frequently than larger diameter stents (10 mm), studies comparing stents with the same diameter have not shown any significant differences among manufacturers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/9,13\">",
"     9,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occluded metal stents can be treated by sweeping debris from within the stent or placing a second stent (plastic or metal) within the lumen of the obstructed stent. Insertion of a plastic or a second metal stent has been shown to be safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Occasionally, the presence of a duodenal stent can hinder attempts at biliary stent placement for the treatment of a malignant biliary stricture; however, fenestration of existing duodenal stents with argon plasma coagulation can facilitate endoscopic retrograde cholangiopancreatography [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517074\">",
"    <span class=\"h3\">",
"     Tissue ingrowth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stents may become occluded by the ingrowth of malignant or nonmalignant tissue. Tumor ingrowth is the most common cause of self-expanding metal stent (SEMS) failure in uncovered stents (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57138 \" href=\"UTD.htm?6/13/6355\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/9,13\">",
"     9,13",
"    </a>",
"    ], but it is much less common with covered stents. (See",
"    <a class=\"local\" href=\"#H1135516991\">",
"     'Covered metal stents'",
"    </a>",
"    above.) In a study of 241 patients treated with uncovered metal stents, stent occlusion occurred in 65 (27 percent), and the most common etiology of stent occlusion was tumor ingrowth (52 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor ingrowth is generally treated by sweeping the stent with an occlusion balloon. If this is not successful, a plastic stent or a SEMS can be placed inside the original stent with good improvement in drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517081\">",
"    <span class=\"h3\">",
"     Tissue overgrowth",
"    </span>",
"    &nbsp;&mdash;&nbsp;As tumor burden increases, tumor overgrowth (ie, occlusion of the ends of the stent by tumor) can cause metal stent occlusion. Overgrowth due to the proliferation of nonmalignant tissue can also occur. Tumor overgrowth was the etiology of stent failure in 11 percent of metal stent occlusions in the trial of 241 patients mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/9\">",
"     9",
"    </a>",
"    ]. A smaller trial with 49 patients receiving SEMS for malignant biliary disease had nine stent failures (18 percent) within a 10 month follow-up. Five of these failures were attributed to tumor overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/38\">",
"     38",
"    </a>",
"    ]. All of the SEMS were partially covered, explaining the high percentage of patients with failure secondary to tumor overgrowth instead of tumor ingrowth. (See",
"    <a class=\"local\" href=\"#H1135516991\">",
"     'Covered metal stents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517088\">",
"    <span class=\"h2\">",
"     Migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like patients with obstruction due to sludge, tumor ingrowth, or tumor overgrowth, patients with stent migrations often present with abdominal pain, elevated liver tests in a cholestatic pattern,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholangitis. Abdominal imaging with a computed tomography scan or magnetic resonance imaging can be helpful in determining if a biliary stent has migrated. However, in practice, if a patient presents with cholestatic liver tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholangitis after biliary stent placement, we often proceed directly to repeat ERCP for diagnosis and management, regardless of the cause (obstruction, migration, etc).",
"   </p>",
"   <p>",
"    Numerous trials have demonstrated very low rates (1 to 2 percent) of stent migration with uncovered metal stents, presumably secondary to embedding of the stent into both the tumor and the surrounding normal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Covered SEMS have a higher rate of migration than uncovered SEMS, ranging from 6 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/10,11,15,16,56\">",
"     10,11,15,16,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sphincterotomy may be a risk factor for stent migration. Studies examining sphincterotomy prior to stent placement have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 74 patients undergoing covered SEMS placement for treatment of unresectable distal biliary obstruction assigned patients to stent placement with or without biliary sphincterotomy to evaluate the rate of stent migration [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/57\">",
"       57",
"      </a>",
"      ]. SEMS were successfully deployed in all patients. Stent migration was more common in patients who received a biliary sphincterotomy compared with those who did not (16 versus 3 percent), but the result did not reach statistical significance (p = 0.075).",
"     </li>",
"     <li>",
"      A retrospective study examined 104 patients receiving a SEMS for malignant biliary stricture (27 with sphincterotomy and 77 without) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/58\">",
"       58",
"      </a>",
"      ]. SEMS placement was successful in all patients. There was no difference between the groups with regard to stent migration (4 percent in both), and uncovered stents were no more likely to migrate than covered stents. Postsphincterotomy bleeding occurred in five patients (19 percent) in the sphincterotomy group compared with none in the no sphincterotomy group (p&lt;0.001).",
"     </li>",
"     <li>",
"      A retrospective study showed a 100 percent success rate of metal stent placement (both covered and uncovered) without prior sphincterotomy, with no cases of stent migration [",
"      <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the above studies, we do not recommend routine biliary sphincterotomy prior to SEMS placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517096\">",
"    <span class=\"h2\">",
"     Cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholecystitis may occur if a covered stent is placed across the origin of the cystic duct, resulting in a functional gallbladder obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In theory, covered stents should cause cholecystitis more often in this situation, but the data thus far have been conflicting. Several studies have demonstrated cholecystitis rates ranging from 0 to 4 percent in patients who receive covered metal biliary stents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. However, other studies suggest the rate may be as high as 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that the rate of cholecystitis may be as high as 10 percent, caution should be used when placing covered metal stents in patients with an intact gallbladder to avoid placing the stent across the cystic duct orifice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5506608\">",
"    <span class=\"h2\">",
"     Cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangitis is a complication of biliary stenting, especially in cases of incomplete drainage. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23959?source=see_link&amp;anchor=H4#H4\">",
"     \"Post-ERCP septic complications\", section on 'Ascending cholangitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517104\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is a potential complication from biliary stent placement and may result from post-sphincterotomy bleeding or bleeding from stent impaction into the duodenal wall. Patients will present with evidence of upper gastrointestinal bleeding and should undergo upper endoscopy. Some patients will have hemobilia and may require endoscopic examination with a side-viewing duodenoscope in order for the diagnosis to be made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Diagnostic studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link&amp;anchor=H13#H13\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\", section on 'Hemobilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective trial comparing metal and plastic stent placement for malignant biliary obstruction found bleeding in 3.6 percent of patients in the metal stent group and 5.4 percent of patients in the plastic stent group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/12\">",
"     12",
"    </a>",
"    ]. Of note, although the sources of the bleeding events were not described, all patients in the trial received a biliary sphincterotomy prior to stent placement, suggesting that the bleeding may not have been directly related to the stents themselves.",
"   </p>",
"   <p>",
"    Perforation and fistula formation are other rare complications of biliary stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Although there have been concerns about possible increased rates of pancreatitis after the placement of a covered metal biliary stent, a retrospective analysis that included 248 patients treated with SEMS found similar rates of pancreatitis between covered and uncovered metal stents (7 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/63/8186/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135517126\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary stents are commonly used in patients with primary pancreaticobiliary malignancy, metastatic disease, and external biliary compression by lymph nodes. By providing biliary decompression they can relieve jaundice and pruritus, while minimizing the risk of developing cholangitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biliary stenting has broad uses in the setting of malignant pancreaticobiliary disease. It is used both as a bridge to surgery in patients with resectable disease and for palliation in patients with biliary obstruction in the setting of unresectable disease. (See",
"      <a class=\"local\" href=\"#H7922055\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Preoperative biliary decompression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of plastic and metal stents, both covered and uncovered, are commercially available. No specific stent has been identified as ideal for all patients. (See",
"      <a class=\"local\" href=\"#H1135516949\">",
"       'Types of stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The placement of a plastic stent is inexpensive and effective, and the stent can be easily removed or exchanged. Plastic stents, however, eventually develop occlusion by sludge",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bacterial biofilm, and maintaining biliary drainage with plastic stents usually requires repeated endoscopic retrograde cholangiopancreatographies. (See",
"      <a class=\"local\" href=\"#H17011418\">",
"       'Patency of plastic stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metal stents extend the duration of stent patency. However, metal stents have significantly higher costs and may not be removable. (See",
"      <a class=\"local\" href=\"#H17011425\">",
"       'Plastic versus metal stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common complications of biliary stent placement include stent occlusion (secondary to",
"      <span class=\"nowrap\">",
"       tissue/tumor",
"      </span>",
"      ingrowth,",
"      <span class=\"nowrap\">",
"       tissue/tumor",
"      </span>",
"      overgrowth,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occlusion by sludge) and stent migration. Less common complications of biliary stent placement include cholecystitis, cholangitis, pancreatitis, perforation, and bleeding. (See",
"      <a class=\"local\" href=\"#H1135517058\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an intact gallbladder who have a confirmed resectable distal malignant biliary obstruction and require biliary drainage prior to surgery, we suggest placement of an uncovered self expanding metal stent (SEMS). Placement of a covered stent may block the cystic duct and lead to cholecystitis. However, cholecystitis can also be seen with uncovered stents, so placement of a covered stent in patient with an intact gallbladder is a reasonable alternative. For patients who have undergone cholecystectomy, we suggest placement of a covered or uncovered SEMS, depending upon the location, geometry, and etiology of the stenosis. (See",
"      <a class=\"local\" href=\"#H7922063\">",
"       'Preoperative biliary drainage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17012786\">",
"       'Preoperative drainage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7922550\">",
"       'Covered versus uncovered metal stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unresectable distal malignant biliary obstruction who have a life expectancy of greater than three months, we suggest placement of a SEMS. If the stent becomes occluded due to",
"      <span class=\"nowrap\">",
"       tissue/tumor",
"      </span>",
"      ingrowth, we suggest placing plastic or additional metal stents within the original metal stent to provide drainage. (See",
"      <a class=\"local\" href=\"#H7922765\">",
"       'Distal obstruction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1135517074\">",
"       'Tissue ingrowth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unresectable distal malignant biliary obstruction who have a life expectancy of less than three months, we suggest placement of a plastic stent. (See",
"      <a class=\"local\" href=\"#H17011425\">",
"       'Plastic versus metal stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hilar obstructions, we suggest stenting of both the right and left systems with either plastic stents or uncovered SEMS to decrease the risk of cholangitis. (See",
"      <a class=\"local\" href=\"#H7922596\">",
"       'Hilar obstruction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/1\">",
"      Siddiqui AA, Mehendiratta V, Loren D, et al. Self-Expanding Metal Stents (SEMS) for Preoperative Biliary Decompression in Patients with Resectable and Borderline-Resectable Pancreatic Cancer: Outcomes in 241 Patients. Dig Dis Sci 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/2\">",
"      Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 2007; 33:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/3\">",
"      Larghi A, Tringali A, Lecca PG, et al. Management of hilar biliary strictures. Am J Gastroenterol 2008; 103:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/4\">",
"      Chen VK, Arguedas MR, Baron TH. Expandable metal biliary stents before pancreaticoduodenectomy for pancreatic cancer: a Monte-Carlo decision analysis. Clin Gastroenterol Hepatol 2005; 3:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/5\">",
"      Chen YK, Jakribettuu V, Springer EW, et al. Safety and efficacy of argon plasma coagulation trimming of malpositioned and migrated biliary metal stents: a controlled study in the porcine model. Am J Gastroenterol 2006; 101:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/6\">",
"      Chun HJ, Kim ES, Hyun JJ, et al. Gastrointestinal and biliary stents. J Gastroenterol Hepatol 2010; 25:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/7\">",
"      Christiaens P, Decock S, Buchel O, et al. Endoscopic trimming of metallic stents with the use of argon plasma. Gastrointest Endosc 2008; 67:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/8\">",
"      Vanbiervliet G, Piche T, Caroli-Bosc FX, et al. Endoscopic argon plasma trimming of biliary and gastrointestinal metallic stents. Endoscopy 2005; 37:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/9\">",
"      Loew BJ, Howell DA, Sanders MK, et al. Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial. Gastrointest Endosc 2009; 70:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/10\">",
"      Yoon WJ, Lee JK, Lee KH, et al. A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction. Gastrointest Endosc 2006; 63:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/11\">",
"      Park do H, Kim MH, Choi JS, et al. Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: a cohort comparative analysis. Clin Gastroenterol Hepatol 2006; 4:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/12\">",
"      Yoon WJ, Ryu JK, Yang KY, et al. A comparison of metal and plastic stents for the relief of jaundice in unresectable malignant biliary obstruction in Korea: an emphasis on cost-effectiveness in a country with a low ERCP cost. Gastrointest Endosc 2009; 70:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/13\">",
"      Yang KY, Ryu JK, Seo JK, et al. A comparison of the Niti-D biliary uncovered stent and the uncovered Wallstent in malignant biliary obstruction. Gastrointest Endosc 2009; 70:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/14\">",
"      Ornellas LC, Stefanidis G, Chuttani R, et al. Covered Wallstents for palliation of malignant biliary obstruction: primary stent placement versus reintervention. Gastrointest Endosc 2009; 70:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/15\">",
"      Kahaleh M, Tokar J, Conaway MR, et al. Efficacy and complications of covered Wallstents in malignant distal biliary obstruction. Gastrointest Endosc 2005; 61:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/16\">",
"      Kahaleh M, Brock A, Conaway MR, et al. Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis. Endoscopy 2007; 39:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/17\">",
"      Lee DK. Drug-eluting stent in malignant biliary obstruction. J Hepatobiliary Pancreat Surg 2009; 16:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/18\">",
"      Lee DK, Kim HS, Kim KS, et al. The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. Gastrointest Endosc 2005; 61:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/19\">",
"      Suk KT, Kim JW, Kim HS, et al. Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. Gastrointest Endosc 2007; 66:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/20\">",
"      Coates JM, Beal SH, Russo JE, et al. Negligible effect of selective preoperative biliary drainage on perioperative resuscitation, morbidity, and mortality in patients undergoing pancreaticoduodenectomy. Arch Surg 2009; 144:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/21\">",
"      van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/22\">",
"      Aadam AA, Evans DB, Khan A, et al. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc 2012; 76:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/23\">",
"      Hochwald SN, Burke EC, Jarnagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999; 134:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/24\">",
"      Liu F, Li Y, Wei Y, Li B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 2011; 56:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/25\">",
"      England RE, Martin DF, Morris J, et al. A prospective randomised multicentre trial comparing 10 Fr Teflon Tannenbaum stents with 10 Fr polyethylene Cotton-Leung stents in patients with malignant common duct strictures. Gut 2000; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/26\">",
"      Terruzzi V, Comin U, De Grazia F, et al. Prospective randomized trial comparing Tannenbaum Teflon and standard polyethylene stents in distal malignant biliary stenosis. Gastrointest Endosc 2000; 51:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/27\">",
"      Kadakia SC, Starnes E. Comparison of 10 French gauge stent with 11.5 French gauge stent in patients with biliary tract diseases. Gastrointest Endosc 1992; 38:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/28\">",
"      Galandi D, Schwarzer G, Bassler D, Allgaier HP. Ursodeoxycholic acid and/or antibiotics for prevention of biliary stent occlusion. Cochrane Database Syst Rev 2002; :CD003043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/29\">",
"      Davids PH, Groen AK, Rauws EA, et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992; 340:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/30\">",
"      Kaassis M, Boyer J, Dumas R, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 2003; 57:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/31\">",
"      Telford JJ, Carr-Locke DL, Baron TH, et al. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc 2010; 72:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/32\">",
"      Kullman E, Frozanpor F, S&ouml;derlund C, et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc 2010; 72:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/33\">",
"      Isayama H, Komatsu Y, Tsujino T, et al. A prospective randomised study of \"covered\" versus \"uncovered\" diamond stents for the management of distal malignant biliary obstruction. Gut 2004; 53:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/34\">",
"      Krokidis M, Fanelli F, Orgera G, et al. Percutaneous palliation of pancreatic head cancer: randomized comparison of ePTFE/FEP-covered versus uncovered nitinol biliary stents. Cardiovasc Intervent Radiol 2011; 34:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/35\">",
"      Krokidis M, Fanelli F, Orgera G, et al. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovasc Intervent Radiol 2010; 33:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/36\">",
"      Saleem A, Leggett CL, Murad MH, Baron TH. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc 2011; 74:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/37\">",
"      Almadi MA, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/38\">",
"      Suk KT, Kim HS, Kim JW, et al. Risk factors for cholecystitis after metal stent placement in malignant biliary obstruction. Gastrointest Endosc 2006; 64:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/39\">",
"      Fumex F, Coumaros D, Napoleon B, et al. Similar performance but higher cholecystitis rate with covered biliary stents: results from a prospective multicenter evaluation. Endoscopy 2006; 38:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/40\">",
"      Abdel Samie A, Dette S, V&ouml;hringer U, et al. Fully covered self-expandable metal stents for treatment of malignant and benign biliary strictures. World J Gastrointest Endosc 2012; 4:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/41\">",
"      Isayama H, Yasuda I, Ryozawa S, et al. Results of a Japanese multicenter, randomized trial of endoscopic stenting for non-resectable pancreatic head cancer (JM-test): Covered Wallstent versus DoubleLayer stent. Dig Endosc 2011; 23:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/42\">",
"      Hwang JC, Kim JH, Lim SG, et al. Y-shaped endoscopic bilateral metal stent placement for malignant hilar biliary obstruction: prospective long-term study. Scand J Gastroenterol 2011; 46:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/43\">",
"      Perdue DG, Freeman ML, DiSario JA, et al. Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction: a prospective multicenter observational cohort study. J Clin Gastroenterol 2008; 42:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/44\">",
"      Peters RA, Williams SG, Lombard M, et al. The management of high-grade hilar strictures by endoscopic insertion of self-expanding metal endoprostheses. Endoscopy 1997; 29:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/45\">",
"      Wagner HJ, Knyrim K, Vakil N, Klose KJ. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy 1993; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/46\">",
"      Sangchan A, Kongkasame W, Pugkhem A, et al. Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc 2012; 76:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/47\">",
"      Dowsett JF, Vaira D, Hatfield AR, et al. Endoscopic biliary therapy using the combined percutaneous and endoscopic technique. Gastroenterology 1989; 96:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/48\">",
"      Deviere J, Baize M, de Toeuf J, Cremer M. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 1988; 34:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/49\">",
"      De Palma GD, Galloro G, Siciliano S, et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/50\">",
"      Naitoh I, Ohara H, Nakazawa T, et al. Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. J Gastroenterol Hepatol 2009; 24:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/51\">",
"      Bang BW, Jeong S, Lee DH, et al. Curved planar reformatted images of MDCT for differentiation of biliary stent occlusion in patients with malignant biliary obstruction. AJR Am J Roentgenol 2010; 194:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/52\">",
"      Weickert U, Zimmerling S, Eickhoff A, et al. A comparative scanning electron microscopic study of biliary and pancreatic stents. Z Gastroenterol 2009; 47:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/53\">",
"      Togawa O, Kawabe T, Isayama H, et al. Management of occluded uncovered metallic stents in patients with malignant distal biliary obstructions using covered metallic stents. J Clin Gastroenterol 2008; 42:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/54\">",
"      Rogart JN, Boghos A, Rossi F, et al. Analysis of endoscopic management of occluded metal biliary stents at a single tertiary care center. Gastrointest Endosc 2008; 68:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/55\">",
"      Topazian M, Baron TH. Endoscopic fenestration of duodenal stents using argon plasma to facilitate ERCP. Gastrointest Endosc 2009; 69:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/56\">",
"      Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 2006; 63:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/57\">",
"      Artifon EL, Sakai P, Ishioka S, et al. Endoscopic sphincterotomy before deployment of covered metal stent is associated with greater complication rate: a prospective randomized control trial. J Clin Gastroenterol 2008; 42:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/58\">",
"      Banerjee N, Hilden K, Baron TH, Adler DG. Endoscopic biliary sphincterotomy is not required for transpapillary SEMS placement for biliary obstruction. Dig Dis Sci 2011; 56:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/59\">",
"      Bharathi RS, Rao PP, Ghosh K. Intra-peritoneal duodenal perforation caused by delayed migration of endobiliary stent: a case report. Int J Surg 2008; 6:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/60\">",
"      Moon SK, Cheung DY, Kim JH, et al. [A case of choledochoduodenal fistula as a delayed complication after biliary metallic stent placement in distal cholangiocarcinoma]. Korean J Gastroenterol 2008; 51:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/61\">",
"      Dokas S, Kotsis V, Milionis G, et al. Fatal upper gastrointestinal bleeding caused by a metal biliary stent despite stent shortening with APC. Endoscopy 2008; 40 Suppl 2:E135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/63/8186/abstract/62\">",
"      Cot&eacute; GA, Kumar N, Ansstas M, et al. Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents. Gastrointest Endosc 2010; 72:748.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13925 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8186=[""].join("\n");
var outline_f7_63_8186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1135517126\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1135516942\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7922055\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7922063\">",
"      Preoperative biliary drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7922070\">",
"      Palliation of unresectable cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7922460\">",
"      - Obstruction of the distal bile duct",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7922078\">",
"      - Obstruction at the hilum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25802026\">",
"      Unknown resectability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1135516949\">",
"      TYPES OF STENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7922269\">",
"      Plastic stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1135516956\">",
"      Metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7923076\">",
"      - Available stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1135516977\">",
"      - Uncovered metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1135516991\">",
"      - Covered metal stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17012685\">",
"      New developments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517012\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17012786\">",
"      Preoperative drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7922765\">",
"      Distal obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17011418\">",
"      - Patency of plastic stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17011425\">",
"      - Plastic versus metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7922550\">",
"      - Covered versus uncovered metal stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7922596\">",
"      Hilar obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17011722\">",
"      - Plastic versus metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17011729\">",
"      - Unilateral versus bilateral stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517058\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5508197\">",
"      Stent occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517066\">",
"      - Stent occlusion due to debris",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517074\">",
"      - Tissue ingrowth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517081\">",
"      - Tissue overgrowth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517088\">",
"      Migration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517096\">",
"      Cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5506608\">",
"      Cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517104\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1135517126\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/13925\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13925|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/13/6355\" title=\"diagnostic image 1\">",
"      Fluoroscopic image of tumor ingrowth into a metal biliary stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13925|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/31/12784\" title=\"picture 1\">",
"      Endoscopic image of a transampullary plastic stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/40/27264\" title=\"picture 2\">",
"      Uncovered biliary stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/63/29681\" title=\"picture 3\">",
"      Endoscopic image of a transampullary uncovered metal stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/10/21665\" title=\"picture 4\">",
"      Endoscopic image of a transampullary covered metal stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13925|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/49/3869\" title=\"table 1\">",
"      Biliary stents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=related_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=related_link\">",
"      Endoscopic management of complications from laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=related_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23959?source=related_link\">",
"      Post-ERCP septic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=related_link\">",
"      Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/51/826?source=related_link\">",
"      The role of endoscopy in biliary complications after liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=related_link\">",
"      Treatment options for locally advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_63_8187="Brain mets prognosis RTOG RPA";
var content_f7_63_8187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognostic groups for outcome after palliative treatment of brain metastases by recursive partitioning analysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prognostic factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median survival, months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        I",
"       </td>",
"       <td>",
"        KPS &ge;70 percent",
"       </td>",
"       <td rowspan=\"4\">",
"        7.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age &lt;65 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Controlled primary site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No extracranial metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        KPS &lt;70",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        All others",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    KPS: Karnofsky performance status.",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Gaspar L, et al. Int J Radiat Oncol Biol Phys 1997; 37:745.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8187=[""].join("\n");
var outline_f7_63_8187=null;
var title_f7_63_8188="Histopathology adnexal masses";
var content_f7_63_8188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histopathology in 656 women with a persistent adnexal mass",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometrioma",
"       </td>",
"       <td>",
"        152",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serous cystadenoma",
"       </td>",
"       <td>",
"        101",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mature teratoma",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhagic cyst",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucinous cystadenoma",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraovarian cyst",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystadenofibroma",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follicular cyst",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian fibroma",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrosalpinx",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuboovarian abscess",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneal cyst",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leiomyoma",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulosa cell tumor",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrothecoma",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"space\" colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant ovarian neoplasm",
"       </td>",
"       <td>",
"        122",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian tumor of low malignant potential",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Guerriero, S, Alcazar, JL, Ajossa, S, et al. Gynecol Oncol 2001; 83:299.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8188=[""].join("\n");
var outline_f7_63_8188=null;
var title_f7_63_8189="Hymenoptera characteristics";
var content_f7_63_8189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of Hymenoptera (bees and wasps)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Common name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical number of adults in a nest",
"       </td>",
"       <td class=\"subtitle1\">",
"        Solitary, but many can occur in the same area",
"       </td>",
"       <td class=\"subtitle1\">",
"        Will sting in defense of the nest",
"       </td>",
"       <td class=\"subtitle1\">",
"        Will not sting unless pinched or handled",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nest",
"       </td>",
"       <td class=\"subtitle1\">",
"        Principal food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Bees",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Honey bee",
"       </td>",
"       <td>",
"        Thousands",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Wax combs in hollow trees, building voids, or manmade hives; Africanized honey bees will nest in many types of cavities",
"       </td>",
"       <td>",
"        Pollen and honey made from nectar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bumble bee",
"       </td>",
"       <td>",
"        Dozens",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Wax pots in the ground or other cavities",
"       </td>",
"       <td>",
"        Pollen and honey made from nectar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carpenter bee",
"       </td>",
"       <td>",
"        One",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        Tunnels in wood trim, fences, and decks",
"       </td>",
"       <td>",
"        Pollen and nectar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sweat bee",
"       </td>",
"       <td>",
"        One",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Pollen and nectar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Wasps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yellowjackets",
"       </td>",
"       <td>",
"        Hundreds to thousands",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Paper combs hidden by envelope and attached to vegetation or buildings, or in the ground or building voids",
"       </td>",
"       <td>",
"        Insects, nectar, ripe fruit; some species scavenge carrion and human food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paper wasps",
"       </td>",
"       <td>",
"        Dozens",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        A single, exposed (no envelope) paper comb with cells open at the bottom",
"       </td>",
"       <td>",
"        Insects (often caterpillars), nectar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        European hornet",
"       </td>",
"       <td>",
"        Hundreds",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Brittle, brown combs, with or without envelope, in hollow trees or building voids",
"       </td>",
"       <td>",
"        Insects (often bees and yellowjackets), ripe fruit, sap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cicada killers",
"       </td>",
"       <td>",
"        One",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        Burrows in the ground",
"       </td>",
"       <td>",
"        Cicadas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mud daubers",
"       </td>",
"       <td>",
"        One",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        Mud lumps or tubes in sheltered areas",
"       </td>",
"       <td>",
"        Spiders",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8189=[""].join("\n");
var outline_f7_63_8189=null;
var title_f7_63_8190="Dialysate flow and solute clearance in PD";
var content_f7_63_8190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dialysate flow and solute clearance in peritoneal dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between dialysate flow rate and clearance of different solutes in peritoneal dialysis. Clearance of small solutes rises with dialysate flow since the delivery of new dialysate containing none of the solute maintains a favorable concentration gradient for continued diffusion. Dialysate flow is less important for larger solutes such as inulin since clearance is too slow for a limiting concentration gradient to be reached.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Popovich, RP, Moncrief, JW, Nolph, KD, et al, Ann Intern Med 1978; 88:449.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8190=[""].join("\n");
var outline_f7_63_8190=null;
var title_f7_63_8191="Inferior vena cavagram showing renal vein thrombosis";
var content_f7_63_8191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inferior vena cavagram showing renal vein thrombosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inferior vena cavagram reveals large clot in area of left renal vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Rose BD, Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_63_8191=[""].join("\n");
var outline_f7_63_8191=null;
